[go: up one dir, main page]

WO2018050028A1 - 一种能够特异性地结合il-17a的抗体及其功能片段 - Google Patents

一种能够特异性地结合il-17a的抗体及其功能片段 Download PDF

Info

Publication number
WO2018050028A1
WO2018050028A1 PCT/CN2017/101083 CN2017101083W WO2018050028A1 WO 2018050028 A1 WO2018050028 A1 WO 2018050028A1 CN 2017101083 W CN2017101083 W CN 2017101083W WO 2018050028 A1 WO2018050028 A1 WO 2018050028A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
antibody
functional fragment
disease
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/101083
Other languages
English (en)
French (fr)
Inventor
宋楠萌
刘家望
杨亚平
杨阳
杨东歌
张红娟
金孟燮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Hanmi Pharmaceutical Co Ltd
Original Assignee
Beijing Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2019535432A priority Critical patent/JP6802381B2/ja
Priority to BR112019004990A priority patent/BR112019004990A2/pt
Priority to US16/332,900 priority patent/US11072651B2/en
Priority to CN201780056725.4A priority patent/CN109715660A/zh
Priority to IL265350A priority patent/IL265350B2/en
Priority to MX2019002970A priority patent/MX2019002970A/es
Priority to ES17850230T priority patent/ES2905917T3/es
Priority to TNP/2019/000082A priority patent/TN2019000082A1/en
Priority to EP17850230.8A priority patent/EP3514176B1/en
Priority to EA201990673A priority patent/EA201990673A1/ru
Priority to KR1020197010362A priority patent/KR102329490B1/ko
Application filed by Beijing Hanmi Pharmaceutical Co Ltd filed Critical Beijing Hanmi Pharmaceutical Co Ltd
Priority to PE2019000527A priority patent/PE20191075A1/es
Priority to MYPI2019001350A priority patent/MY185578A/en
Priority to CA3036913A priority patent/CA3036913C/en
Priority to NZ752189A priority patent/NZ752189B2/en
Priority to AU2017328310A priority patent/AU2017328310B2/en
Publication of WO2018050028A1 publication Critical patent/WO2018050028A1/zh
Priority to SA519401307A priority patent/SA519401307B1/ar
Priority to CONC2019/0002370A priority patent/CO2019002370A2/es
Priority to PH12019500551A priority patent/PH12019500551A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to the field of medical biotechnology and humanized antibody engineering research, and in particular to an antibody capable of specifically binding to IL-17A and functional fragments thereof.
  • Interleukin-17A is a pro-inflammatory cytokine produced primarily from Th17 cells and is the most representative member of the IL-17 family (Miossec P, Kolls JK. Nat. Rev .Drug.Discov., 2012, 11: 763-776).
  • IL-17A binds to its receptor (IL-17RA)
  • IL-17RA receptor
  • IL-17RA IL-17RA
  • IL-17A acts on macrophages, DC cells, induces high expression of IL-1, IL-6, TNF, CRP, leading to inflammatory reaction, involved in the pathological process of psoriasis and transplant rejection;
  • IL-17A acts on the endothelium Cells, induced by IL-6, MMP, high expression of coagulation factors, leading to vascular activation, involved in pathological processes of reperfusion injury, thrombosis and atherosclerosis;
  • IL-17A acts on fibroblasts, induces IL-6, chemotaxis Factor, growth factor, high expression of MMP, lead to matrix destruction, participate in the pathological process of multiple sclerosis, cloning enemies;
  • IL-17A acts on osteoblasts and chondrocytes, induces RANKL, MMP, osteoclastogenesis, leading to Bone erosion, cartilage damage, and pathological processes involved in rheumatoid arthritis and
  • IL-17A neutralizing antibody can inhibit the high expression of IL-17A in synovial tissue of patients with rheumatoid arthritis and reduce the production of important inflammatory factor IL-6 (Chabaud M, Durand JM, Buchs N, et al. Arthritis Rheum. 1999) , 42:963-70). Animal models of many autoimmune diseases have demonstrated that the use of antibodies to neutralize IL-17A can effectively inhibit the pathological development of inflammation (Lubberts E, Koenders MI, Oppers-Walgreen B, et al. Arthritis Rheum., 2004, 50: 650- 659).
  • IL-17A-related antibody drugs have been approved for marketing, namely Secukinumab (IL-17A targeting antibody) and Ixekizumab (IL-17A targeting antibody), both for the treatment of psoriasis.
  • IL-17A targeting antibody Secukinumab
  • Ixekizumab Ixekizumab
  • these drugs do not exhibit the desired therapeutic effect for certain chronic inflammatory diseases such as rheumatoid arthritis (Kellner H, Ther Adv Musculoskelet Dis., 2013, 5: 141-152).
  • the invention is based on a obtained monoclonal antibody against human IL-17A which specifically binds to human IL-17A protein, and the CDR region sequence is determined by cloning, identification and gene structure analysis, and the invention is constructed.
  • the corresponding chimeric antibody and humanized antibody, and the corresponding eukaryotic cell expression system were established, and the chimeric antibody and the humanized antibody were produced and purified.
  • the light chain has a light chain CDR consisting of CDR-L1, CDR-L2, CDR-L3;
  • the heavy chain has a heavy chain CDR consisting of CDR-H1, CDR-H2, CDR-H3;
  • amino acid sequences of the CDR-L1, CDR-L2, and CDR-L3 are shown in SEQ ID NOs: 1, 2, and 3, respectively; the amino acid sequences of the CDR-H1, CDR-H2, and CDR-H3 are respectively SEQ ID NO: 4, 5 and 6;
  • the antibody or functional fragment thereof comprises an IL-17A chimeric antibody and a functional fragment thereof, and an IL-17A humanized antibody and functional fragments thereof.
  • the antibody or a functional fragment thereof comprises an IL-17A chimeric antibody and a functional fragment thereof, or
  • the antibody or functional fragment thereof includes an IL-17A humanized antibody and functional fragments thereof.
  • the binding specificity and affinity of an antibody are mainly determined by the CDR sequence, and the amino acid sequence of the non-CDR region can be easily changed according to the mature and well-known existing techniques to obtain a similar biological activity. body.
  • the monoclonal antibody variants of the present invention having CDR sequences identical to those of the above CDR sequences, which have identical CDR sequences as the humanized antibodies of the present invention, have similar biological activities.
  • the antibody and functional fragment thereof as described above wherein the antibody comprises a sequence selected from a constant region of any one of the group consisting of human antibodies IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, IgD.
  • a “functional fragment” as used herein refers specifically to an antibody fragment having the same specificity as IL-1A for the parent antibody. In addition to the above functional fragments, any fragment whose half-life has been increased is also included.
  • the antibody fragment of the present invention can obtain the above functions by a method such as enzymatic digestion (including pepsin or papain) and/or a method of chemically reducing split disulfide bonds. Fragment.
  • Antibody fragments can also be obtained by peptide synthesis by recombinant genetic techniques also known to those skilled in the art or by automated peptide synthesizers such as an automated peptide synthesizer, such as Applied BioSystems.
  • the antibody and functional fragment thereof as described above the amino acid sequence of the light chain variable region sequence and the heavy chain variable region sequence of the IL-17A chimeric antibody and functional fragment thereof are SEQ ID NO: 7 and SEQ ID NO:8.
  • the amino acid sequences of the light chain constant region sequence and the heavy chain constant region sequence of the IL-17A chimeric antibody and functional fragment thereof are SEQ ID NO: 9 and SEQ, respectively. ID NO: 10 is shown.
  • the antibody and functional fragment thereof as described above the light chain backbone region of the IL-17A humanized antibody and functional fragment thereof comprises FR-L1, FR-L2, FR-L3 and FR-L4, heavy chain
  • the skeleton area includes FR-H1, FR-H2, FR-H3 and FR-H4;
  • amino acid sequences of FR-L1, FR-L2, FR-L3 and FR-L4 are sequentially shown as SEQ ID NOS: 11-14;
  • amino acid sequences of the FR-H1, FR-H2, FR-H3 and FR-H4 are sequentially shown as SEQ ID NOS: 15-18;
  • the CDR is the main relevant site of antigen binding, but in most cases, the FR (Framework region) has a significant influence on the conformation of the binding site.
  • the present invention selects a suitable FR region and correlates The FR residue needs to be returned to the original mouse amino acid or other amino acids visible in the same person.
  • the FR-L1 is selected from the amino acid sequence shown in SEQ ID NO: 11, or the amino sequence obtained by the following substitutions and combinations thereof:
  • the first amino acid D is replaced by I;
  • the second amino acid V is replaced by I;
  • the FR-L2 is selected from the amino acid sequence shown in SEQ ID NO: 12, or the amino sequence obtained by the following substitutions and combinations thereof:
  • the 14th amino acid R is replaced by L;
  • the FR-L3 is selected from the amino acid sequence shown in SEQ ID NO: 13, or an amino sequence obtained by the following substitutions and combinations thereof:
  • the FR-L4 is selected from the amino acid sequence shown in SEQ ID NO: 14;
  • the FR-H1 is selected from the amino acid sequence shown in SEQ ID NO: 15, or is obtained by the following substitutions and combinations thereof Amino sequence:
  • the fourth amino acid L is replaced by V;
  • the FR-H2 is selected from the amino acid sequence shown in SEQ ID NO: 16, or an amino sequence obtained by the following substitutions and combinations thereof:
  • the FR-H3 is selected from the amino acid sequence shown in SEQ ID NO: 17, or an amino sequence obtained by the following substitutions and combinations thereof:
  • the second amino acid V is replaced by I;
  • the light chain variable region sequence of the IL-17A humanized antibody and functional fragment thereof is as set forth in any one of SEQ ID NOs: 19-26;
  • the heavy chain variable region sequence of the IL-17A humanized antibody and functional fragment thereof is as set forth in any one of SEQ ID NOs: 27-34;
  • the light chain variable region sequence of the IL-17A humanized antibody and functional fragment thereof is set forth in SEQ ID NO: 19; the corresponding heavy chain variable region sequence is set forth in SEQ ID NO: 27. ;
  • the light chain variable region sequence of the IL-17A humanized antibody and functional fragment thereof is set forth in SEQ ID NO: 20; the corresponding heavy chain variable region sequence is set forth in SEQ ID NO: 28.
  • the light chain variable region sequence of the IL-17A humanized antibody and functional fragment thereof is set forth in SEQ ID NO: 21; the corresponding heavy chain variable region sequence is set forth in SEQ ID NO: 29;
  • the light chain variable region sequence of the IL-17A humanized antibody and functional fragment thereof is set forth in SEQ ID NO: 22; the corresponding heavy chain variable region sequence is set forth in SEQ ID NO: 30;
  • the light chain variable region sequence of the IL-17A humanized antibody and functional fragment thereof is set forth in SEQ ID NO: 22; the corresponding heavy chain variable region sequence is set forth in SEQ ID NO: 31;
  • the light chain variable region sequence of the IL-17A humanized antibody and functional fragment thereof is set forth in SEQ ID NO: 23; the corresponding heavy chain variable region sequence is set forth in SEQ ID NO: 32;
  • the light chain variable region sequence of the IL-17A humanized antibody and functional fragment thereof is set forth in SEQ ID NO: 24; the corresponding heavy chain variable region sequence is set forth in SEQ ID NO: 33;
  • the light chain variable region sequence of the IL-17A humanized antibody and functional fragment thereof is set forth in SEQ ID NO: 25; the corresponding heavy chain variable region sequence is set forth in SEQ ID NO: 32;
  • the light chain variable region sequence of the IL-17A humanized antibody and functional fragment thereof is set forth in SEQ ID NO: 26; the corresponding heavy chain variable region sequence is set forth in SEQ ID NO: 34;
  • amino acid sequences of the light chain constant region sequence and the heavy chain constant region sequence of the IL-17A humanized antibody and functional fragment thereof are set forth in SEQ ID NO: 9 and SEQ ID NO: 10, respectively.
  • the light chain constant region of the IL-17A humanized antibody and functional fragment thereof is selected from the human antibody Kappa light chain constant region, the amino acid sequence of which is set forth in SEQ ID NO:9;
  • the heavy chain constant region of the IL-17A humanized antibody and functional fragment thereof is selected from the human antibody IgG1 heavy chain constant region, the amino acid sequence of which is set forth in SEQ ID NO: 10.
  • chimeric antibodies and humanized antibodies can be achieved by any method known to those skilled in the art, such as by designing CDRs based on the sequence of murine antibodies.
  • the immunized animal can include a transgenic mouse having a human immunoglobulin locus and then directly producing a human antibody.
  • Another possible embodiment can include screening the library using phage display technology.
  • nucleic acid molecule selected from the group consisting of:
  • a vector comprising a nucleic acid molecule as described above.
  • the invention further comprises at least one nuclear construct encoding a nucleic acid molecule as described above, preferably a vector, further preferably an expression vector, such as a plasmid, which is described in one embodiment of the present application.
  • a host cell transformed with a vector as described above A host cell transformed with a vector as described above.
  • the host cell is a eukaryotic cell, such as a mammalian cell.
  • a method of producing an antibody capable of specifically binding to IL-17A and a functional fragment thereof comprising the steps of:
  • the host cells as described above are cultured in a medium and under suitable culture conditions;
  • the antibody thus produced and its functional fragments are recovered from the culture medium or from the cultured host cells.
  • composition comprising, as an active ingredient, an antibody and/or a functional fragment thereof as described above, or a compound thereof and other components.
  • the antibody and functional fragments thereof are coupled to at least one diagnostic and/or therapeutic agent to form an immunoconjugate.
  • the diagnostic agent is selected from the group consisting of a radionuclide, a radioactive contrast agent, a paramagnetic ion, a metal, a fluorescent label, a chemiluminescent label, an ultrasound contrast agent, and a photosensitizer. Species or more;
  • the radionuclide comprises a group selected from the group consisting of 110 In, 111 In, 177 Lu, 18 F, 52 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 86 Y, 90 Y, 89 Zr, 94 mTc, 94 Tc, 99 mTc, 120 I, 123 I, 124 I, 125 I, 131 I, 154-158 Gd, 32 P, 11 C, 13 N, 15 O, 186 Re, 188 Re, 51 Mn, One or more of the group consisting of 52 mMn, 55 Co, 72 As, 75 Br, 76 Br, 82 mRb, and 83 Sr;
  • the paramagnetic ion comprises a group selected from the group consisting of chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), and cerium (III).
  • chromium (III) manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), and cerium (III).
  • cerium (III), cerium (III), cerium (III), vanadium (II), cerium (III), cerium (III), cerium (III) and cerium (III) chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), and cerium (III).
  • the fluorescent label is selected from the group consisting of Alexa 350, Alexa 405, Alexa 430, Alexa 488, Alexa 555, Alexa 647, AMCA, amino acridine, BODIPY 630/650, BODIPY 650/665, BODIPY-FL, BODIPY-R6G , BODIPY-TMR, BODIPY-TRX, 5-carboxy-4', 5'-dichloro-2', 7'-dimethoxyfluorescein, 5-carboxy-2', 4', 5', 7' - tetrachlorofluorescein, 5-carboxyfluorescein, 5-carboxyrhodamine, 6-carboxyrhodamine, 6-carboxytetramethylrhodamine, Cascade Blue, Cy2, Cy3, Cy5, Cy7, 6-FAM, Dansul Acid chloride, fluorescein, HEX, 6-JOE, NBD (7-nitrobenzo-2-oxa-1
  • the therapeutic agent is selected from the group consisting of a naked antibody, a cytotoxic agent, a drug, a radionuclide, a boron atom, an immunomodulator, an anti-apoptotic agent, a photosensitizing therapeutic agent, an immunoconjugate And one or more of the groups consisting of the oligonucleotides;
  • the drug is selected from the group consisting of dexamethasone, diclofenac, nabumetone, meloxicam, celecoxib, methotrexate, cyclophosphamide, azathioprine, cyclosporine A and vincristine One or more of the group consisting of;
  • the oligonucleotide is selected from one or more of the group consisting of shRNA, miRNA and siRNA;
  • the immunomodulator is selected from the group consisting of a cytokine, a chemokine, a stem cell growth factor, a lymphotoxin, a hematopoietic factor, a colony stimulating factor (CSF), an interferon, an erythropoietin, a thrombopoietin, an interleukin (IL).
  • a cytokine a chemokine
  • stem cell growth factor a lymphotoxin
  • a hematopoietic factor a colony stimulating factor (CSF)
  • CSF colony stimulating factor
  • IL interleukin
  • G-CSF granulocyte-colony stimulating factor
  • GM-CSF granulocyte macrophage-colony stimulating factor
  • stem cell growth factor granulocyte macrophage-colony stimulating factor
  • the cytokine is preferably selected from the group consisting of human growth hormone, N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, relaxin, and stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), liver growth factor, prostaglandin, fibroblast growth factor, prolactin Placental, placental lactogen, OB protein, tumor necrosis factor- ⁇ , tumor necrosis factor- ⁇ , mullerian inhibitor, mouse gonadotropin-related peptide, inhibin, activin, vascular endothelial growth factor, integrin , thrombopoietin (TPO), NGF- ⁇ , platelet-growth factor, TGF- ⁇ , TGF- ⁇ , insulin-like growth factor-I, insulin-like growth factor-II, erythropoietin (EPO), osteoinduction Factor, interferon- ⁇ , interferon- ⁇ ,
  • IL-18, IL-21, IL-25, LIF, FLT-3, angiostatin, thrombospondin, endostatin, tumor necrosis factor and LT One or more of the group consisting of IL-18, IL-21, IL-25, LIF, FLT-3, angiostatin, thrombospondin, endostatin, tumor necrosis factor and LT.
  • the chemokine is preferably selected from one or more of the group consisting of RANTES, MCAF, MIP1- ⁇ , MIP1- ⁇ , and IP-10.
  • the radionuclide is selected from the group consisting of 111 In, 111 At, 177 Lu, 211 Bi, 212 Bi, 213 Bi, 211 At, 62 Cu, 67 Cu, 90 Y, 125 I, 131 I, 133 I, 32 P, 33 P, 47 Sc, 111 Ag, 67 Ga, 153 Sm, 161 Tb, 152 Dy, 166 Dy, 161 Ho, 166 Ho, 186 Re, 188 Re, 189 Re, 211 Pb, 212 Pb, 223 Ra, 225 Ac, 77 As, 89 Sr, 99 Mo, 105 Rh, 149 Pm, 169 Er, 194 Ir, 58 Co, 80 mBr, 99 mTc, 103 mRh, 109 Pt, 119 Sb, 189 mOs, 192 Ir, 219 Rn 215 Po, 221 Fr, 255 Fm, 11 C, 13 N, 15 O, 75 Br, 198 Au, 199 Au,
  • compositions as described above for the manufacture of a medicament for the prevention and/or treatment of a disease associated with overexpression and/or release of IL-17A;
  • the disease is selected from the group consisting of airway inflammation, asthma, bronchial asthma, allergic asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and silver swarf Arthritis, psoriasis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, lupus nephritis, scleroderma, ulcerative colitis, inflammatory bowel disease, uveitis, Helicobacter pylori-associated gastritis , osteoporosis, bone erosion, intraperitoneal abscess and adhesions, Addison's disease, gamma globulin deficiency, alopecia areata, celiac disease, Chagas disease, Crohn's disease, allograft rejection, Behcet's disease Any of the groups
  • an antibody capable of specifically binding IL-17A and a functional fragment thereof as described above for the preparation of a medicament for preventing and/or treating a disease associated with overexpression and/or release of IL-17A.
  • a medicament prepared for preventing and/or treating a disease associated with overexpression and/or release of IL-17A which comprises an antibody capable of specifically binding IL-17A as described above and a functional fragment thereof, and a medicinal Acceptable carrier;
  • the medicament contains a composition as described above and a pharmaceutically acceptable carrier.
  • the term “pharmaceutically acceptable” means that the compound is physiologically acceptable when the compound is administered to a human, and does not cause an allergic reaction such as a gastrointestinal disorder, dizziness or the like or a systemic allergic reaction similar to these allergic reactions. .
  • "pharmaceutically acceptable carrier” includes, but is not limited to, binders (such as microcrystalline cellulose, alginates, gelatin, and polyvinylpyrrolidone), fillers (such as starch, sucrose, glucose, and Anhydrous lactic acid), disintegrants (such as cross-linked PVP, croscarmellose sodium, croscarmellose sodium, and low-substituted hydroxypropylcellulose), lubricants (magnesium stearate, hard Aluminum oleate, talc, polyethylene glycol, sodium benzoate), wetting agents (such as glycerin), surfactants (such as cetyl alcohol), and absorption enhancers, flavoring agents, sweeteners, thinners, bags Clothes and so on.
  • binders such as microcrystalline cellulose, alginates, gelatin, and polyvinylpyrrolidone
  • fillers such as starch, sucrose, glucose, and Anhydrous lactic acid
  • disintegrants such as cross-linked PVP
  • the disease as described above is selected from the group consisting of airway inflammation, asthma, bronchial asthma, allergic asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis Arthritis, psoriasis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, lupus nephritis, scleroderma, ulcerative colitis, inflammatory bowel disease, uveitis, Helicobacter pylori-associated gastritis, Osteoporosis, bone erosion, intraperitoneal abscess and adhesion, Addison's disease, gamma globulin deficiency, alopecia areata, celiac disease, Chagas disease, Crohn's disease, allograft rejection, Behcet's disease, Any of
  • the above-mentioned individual is a human, and further, the above-mentioned individual is in need of prevention and/or treatment with an IL-17A excess table.
  • the disease as described above is selected from the group consisting of airway inflammation, asthma, bronchial asthma, allergic asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis Arthritis, psoriasis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, lupus nephritis, scleroderma, ulcerative colitis, inflammatory bowel disease, uveitis, Helicobacter pylori-associated gastritis, Osteoporosis, bone erosion, intraperitoneal abscess and adhesion, Addison's disease, gamma globulin deficiency, alopecia areata, celiac disease, Chagas disease, Crohn's disease, allograft rejection, Behcet's disease, Any of
  • Example 1 is a binding activity of a monoclonal antibody secreted by clone No. 88 to human IL-17A in Example 1 of the present invention
  • FIG. 2 is a neutralization activity of a monoclonal antibody secreted by clone No. 88 in the first embodiment of the present invention for human IL-17A-stimulated secretion of human IL-6 by HFF-1 cells;
  • Figure 3 is a species specificity of an anti-human IL-17A chimeric monoclonal antibody according to Example 4 of the present invention.
  • Figure 4 is a binding specificity of an anti-human IL-17A chimeric mAb in Example 4 of the present invention.
  • Figure 5 is an in vitro neutralizing activity of an anti-human IL-17A chimeric monoclonal antibody according to Example 5 of the present invention.
  • Figure 6 is an in vivo neutralizing activity of an anti-human IL-17A chimeric monoclonal antibody according to Example 6 of the present invention.
  • Figure 7 is a time chart of a single intravenous injection in Example 7 of the present invention.
  • Figure 8 is the antigen binding activity of anti-human IL-17A humanized mAb in Example 9 of the present invention.
  • Figure 9 is an in vitro neutralizing activity of anti-human IL-17A humanized mAb in Example 10 of the present invention.
  • Figure 10 is a graph showing the drug time after a single subcutaneous injection in Example 15 of the present invention.
  • mice were selected from female BALB/c mice, 6 to 8 weeks old, purchased from Beijing Huakang Biotechnology Co., Ltd.
  • immunization began.
  • the recombinant human IL-17A protein was expressed by E. coli, and the inclusion bodies were collected and subjected to renaturation treatment to obtain soluble IL-17A protein.
  • 100 ⁇ g of recombinant human IL-17A protein was mixed with Freund's complete adjuvant (Sigma-Aldrich, Cat. No. F5881) to form an emulsion, which was intraperitoneally injected into mice. Two weeks later, booster immunizations were performed.
  • Enhancement immunization 50 ⁇ g of recombinant human IL-17A protein was mixed with Freund's incomplete adjuvant (Sigma-Aldrich, Cat. No. F5806) to form an emulsion, which was intraperitoneally injected into mice.
  • the immunization was boosted in the same way every 2 weeks, and the immunization was boosted 3 times.
  • blood was collected from the posterior venous plexus of the mouse and centrifuged, and the antibody titer was determined by ELISA. Mice with high titers were selected for fusion to make hybridomas.
  • the logarithmic growth of myeloma cells SP2/0 was centrifuged at 1000 rpm for 5 minutes, the supernatant was discarded, and the cells were suspended with incomplete DMEM medium (Gibco, cat No. 11965), and counted, and the required number of cells was used. The whole culture solution was washed twice. At the same time, an immunosplenic cell suspension was prepared and washed twice with an incomplete culture solution. The myeloma cells and the spleen cells were mixed at a ratio of 1:10 or 1:5, and washed once with an incomplete culture solution in a 50 ml plastic centrifuge tube at 1200 rpm for 8 minutes.
  • the 96-well cell culture plates were dispensed in 0.1 ml per well; the 24-well plates were dispensed in 1.0-1.5 ml per well; then the plates were incubated at 37 ° C in a 6% CO 2 incubator. Generally, six 96-well plates are laid. After 5 days, 1/2 medium was exchanged with HAT medium. After another 7 to 10 days, HAT medium was exchanged with HT medium (DMEM + HT, Sigma cat No. H0137-10 VL). The growth of hybridoma cells is often observed, and the supernatant is aspirated for antibody detection until it reaches a cell bottom area of 1/10 or more. The positive cloned cells were expanded and frozen.
  • ELISA was used to screen anti-human IL-17A antibodies from hybridoma culture supernatants.
  • Wash PBST 5 times Block with 300 ⁇ L/well in PBST containing 1% BSA and incubate for 1 hour at 25 °C. Wash PBST 5 times.
  • the culture supernatant sample and the positive control were added, 100 ⁇ L was added to each well, and incubation was carried out for 1 hour at 25 °C. Wash PBST 5 times. Then, horseradish peroxidase-labeled anti-mouse IgG antibody (Abeam, Cat. No. A7068) diluted 1:10000 in PBST containing 1% BSA was added, 100 ⁇ L was added to each well, and incubation was carried out for 1 hour at 25 °C. Wash PBST 5 times. The colorimetric substrate TMB was added at 100 ⁇ L/well and developed for 10 minutes at room temperature. Color development was stopped by adding 1 M H 2 SO 4 at 100 ⁇ L/well. The absorbance at 450 nm was read on a microplate reader. Positive clones capable of secreting anti-human IL-17A binding antibodies were selected based on the strength of OD450nm.
  • IL-17A Cell assays determine whether anti-human IL-17A antibodies secreted by positive clones are neutralizing antibodies.
  • the anti-human IL-17A antibody sample was diluted in DMEM (GIBCO, Cat. No. 11995-073) complete medium containing 10% FBS (Hyclone, Cat. No. SH30084.03), and the initial concentration of the sample was 160 nM (final concentration 40 nM), 5
  • the sequence was diluted, 50 ⁇ L per well, and added to the cell culture plate.
  • Human IL-17A at a concentration of 20 ng/mL (final concentration 5 ng/mL) diluted to the same complete medium was added to the cell culture plate at 50 ⁇ L per well.
  • clone No. 88 had strong human IL-17A binding activity, and according to Fig. 2, clone No. 88 also had strong human IL-17A neutralizing activity.
  • a clone having both antigen-binding activity and antigen-neutralizing activity obtained by screening was subjected to measurement of an antibody DNA sequence.
  • Cellular mRNA was first extracted using RNAprep Pure Kit (Tiangen, DP430). The procedure was as follows: collection of suspension cells was performed at 1 ⁇ 10 7 , centrifuged at 300 ⁇ g for 5 min, and the cells were collected into a centrifuge tube, and all the culture supernatants were carefully aspirated. The lysis step is carried out immediately. Flick the bottom of the centrifuge tube to loosen the cell pellet, add appropriate amount of lysate RL600uL, and vortex.
  • 350 ⁇ l of the deproteinized liquid RW1 was added to the adsorption column CR3, and centrifuged at 12,000 rpm ( ⁇ 13,400 ⁇ g) for 30 to 60 sec.
  • the waste liquid in the collection tube was drained, and the adsorption column CR3 was placed back in the collection tube.
  • 80 ⁇ l of DNase I working solution was added to the center of the adsorption column CR3 and allowed to stand at room temperature for 15 min.
  • 350 ⁇ l of the deproteinized liquid RW1 was added to the adsorption column CR3, and centrifuged at 12,000 rpm ( ⁇ 13,400 ⁇ g) for 30 to 60 sec.
  • the waste liquid in the collection tube was drained, and the adsorption column CR3 was placed back in the collection tube.
  • the adsorption column CR3 was transferred to a new RNase-Free centrifuge tube, and 30 to 100 ⁇ l of RNase-Free ddH 2 O was added thereto for 2 min, and centrifuged at 12,000 rpm ( ⁇ 13,400 ⁇ g) for 2 min to obtain an RNA solution.
  • the first strand of cDNA was synthesized using the QuantScript RT kit (Tiangen, KR103). The procedure is as follows, the template RNA is thawed on ice; the primer, 10 ⁇ RT mix (which contains RNasin and DTT), Super pure dNTP mixture, RNase-Free ddH 2 O are thawed at room temperature (15-25 ° C), and quickly thawed. Place on ice. Each solution was vortexed and mixed before use, and briefly centrifuged to collect the liquid remaining on the tube wall. Use the primers in Table 1 to configure the reverse transcription system mixture (Tiangen Bio Quant cDNA First-Strand Synthesis Kit, Catalog No.
  • the primers used in the PCR reaction are shown in Table 1.
  • VH primer F1 GAGGTGAAGCTGCAGGAGTCAGGACCTAGCCTGGTG
  • R1 AGGT (C/G) (A/C) AACTGCAG (C/G) AGTC (A/T) GG
  • R2 AGGT (C/G) (A/C) AGCTGCAG (C/G) AGTC (A/T) GG
  • R3 AGGT(C/G)CAGCTGCAG(C/G)AGTC(A/T)GG
  • R4 CCAGGGGCCAGTGGATAGACAAGCTTGGGTGTCGTTTT
  • F2 ATAGACAGATGGGGGTGTCGTTTTGGC
  • F4 AGGGGCCAGTGGATAGACTGATGG
  • F5 AGGGACCAAGGGATAGACAGATGG
  • R5 (G/C) A (A/G) GT (A/T/C/G) (A/C) AGCTG (G/C) AG (G/C) AGTC R6:
  • any upstream primer in the VH primer can be used with either downstream primer; any upstream primer in the VL primer can also be used with any downstream primer.
  • the target band obtained by PCR amplification was cloned into the pGEM-T vector. Pick a single clone for DNA sequencing.
  • the amino acid sequence of the antibody light chain variable region obtained by PCR amplification is shown in SEQ ID NO: 7, and the amino acid sequence of the antibody heavy chain variable region is shown in SEQ ID NO: 8.
  • the sequence of the complementarity determining region can be obtained by excluding the sequence of the framework region from the mouse variable region sequence; wherein the amino acid sequences of the three complementarity determining regions CDR-L1, CDR-L2 and CDR-L3 of the light chain are respectively SEQ ID NO: 1, 2 and 3; the amino acid sequences of the three complementarity determining regions CDR-H1, CDR-H2, CDR-H3 of the heavy chain are shown in SEQ ID NOs: 4, 5 and 6, respectively.
  • the amino acid sequence of the antibody light chain constant region is set forth in SEQ ID NO: 9, and the amino acid sequence of the antibody heavy chain constant region is set forth in SEQ ID NO: 10.
  • the above antibody light chain (the full length of the light chain is SEQ ID NO: 7 and SEQ ID NO: 9) and the heavy chain (the full length of the heavy chain will be SEQ ID NO: 8 and SEQ ID NO:
  • the nucleic acid sequence of 10 ligated into the eukaryotic expression vector X0GC (wherein the antibody light chain full-length nucleic acid sequence is shown in SEQ ID NO: 23, and the antibody heavy chain full-length nucleic acid sequence is shown in SEQ ID NO: 24) , then the expression vector was transfected 293F cell line (FreeStyle TM 293F cells, NO R79007, invitrogen).
  • transfected cells 200 ⁇ 10 5 cells were collected the day of the cells, the cells were resuspended in fresh FreeStyle TM 293 expression medium (FreeStyle TM 293Expression Medium, NO 12338001, Gibco) in a cell density of /mL.
  • FreeStyle TM 293Expression Medium FreeStyle TM 293Expression Medium, NO 12338001, Gibco
  • the plasmid was added to the transfection volume at a final concentration of 36.67 ug/mL and gently mixed; then linear PEI (polyethyleneimine, linear, MW 25000, Cat. No. 43896, Alfa Aesar) was added at a final concentration of 55 ug/mL. Mix well.
  • the cells were placed in a cell culture incubator and incubated at 37 ° C for 1 hour at 120 rpm. A 19-fold transfection volume of fresh medium was then added. Continue to incubate at 37 ° C with a 120 rpm shaker. The cell culture supernatant transfected for 5-6 days was collected by centrifugation.
  • the kinetic constant of binding of anti-human IL-17A monoclonal antibody to its antigen human IL-17A was measured using a Biacore 3000 instrument.
  • the instrument utilizes an optical surface plasmon resonance technique to detect binding and dissociation between a molecule coated on a biochip and a molecule to be tested.
  • the main reagents used were amino coupling kits (GE Healthcare, BR-1000-14) and CM5 chips (GE Healthcare, BR-1000-50).
  • anti-human IL-17A monoclonal antibody Compared with secukinumab, anti-human IL-17A monoclonal antibody has a smaller dissociation equilibrium constant, stronger affinity, especially after binding to IL-17A antigen, it can maintain the binding state for a longer time, and it is more difficult to dissociate. Biological functions are very beneficial.
  • Example 4 Species specificity and binding specificity of chimeric anti-human IL-17A monoclonal antibody
  • the species specificity of the anti-human IL-17A chimeric monoclonal antibody was determined by ELISA.
  • the coating concentration was 1 ⁇ g/mL, the coating amount was 100 ⁇ L per well, and the coating was carried out overnight at 4 °C. Wash PBST 5 times. Block with 300 ⁇ L/well in PBST containing 1% BSA and incubate for 1 hour at 25 °C. Wash PBST 5 times.
  • the anti-human IL-17A chimeric monoclonal antibody sample diluted in PBST containing 1% BSA and the control were added, and 100 ⁇ L was added to each well, and incubated at 25 ° C for 1 hour. Wash PBST 5 times. Then, horseradish peroxidase-labeled anti-human IgG antibody (Chemicon, Cat. No. AP309P) diluted 1:2000 in PBST containing 1% BSA was added, 100 ⁇ L per well was added, and incubation was carried out for 1 hour at 25 °C. Wash PBST 5 times. The colorimetric substrate TMB was added at 100 ⁇ L/well and developed for 10 minutes at room temperature. Color development was stopped by adding 1 MH 2 SO 4 at 100 ⁇ L/well. The absorbance at 450 nm was read on a microplate reader.
  • the binding specificity of the anti-human IL-17A chimeric monoclonal antibody was determined by ELISA.
  • IL-2, IL-6, IL-8, IL-21, IL-22, IL-23, IFN-g and TNFa purchasedd from Beijing Yiqiao Shenzhou or R&D systems
  • the coating amount was 100 ⁇ L per well, and the coating was carried out overnight at 4 °C.
  • Wash PBST 5 times Block with 300 ⁇ L/well in PBST containing 1% BSA and incubate for 1 hour at 25 °C. Wash PBST 5 times. Anti-human IL-17A chimeric monoclonal antibody samples diluted in PBST containing 1% BSA and controls were added, 100 ⁇ L per well, and incubated at 25 ° C for 1 hour. Wash PBST 5 times. Then, horseradish peroxidase-labeled anti-human IgG antibody (Chemicon, Cat. No. AP309P) diluted 1:2000 in PBST containing 1% BSA was added, 100 ⁇ L per well was added, and incubation was carried out for 1 hour at 25 °C.
  • horseradish peroxidase-labeled anti-human IgG antibody (Chemicon, Cat. No. AP309P) diluted 1:2000 in PBST containing 1% BSA was added, 100 ⁇ L per well was added, and incubation was carried
  • the anti-human IL-17A chimeric monoclonal antibody can bind to human, monkey IL-17A, but does not bind to rat, mouse IL-17A, and is species-specific.
  • the anti-human IL-17A chimeric monoclonal antibody also has strong binding specificity, binding only to IL-17A, not binding to other cytokines of the IL-17 family, and unrelated cytokines. .
  • the anti-human IL-17A antibody sample was diluted in DMEM (GIBCO, Cat. No. 11995-073) complete medium containing 10% FBS (Hyclone, Cat. No. SH30084.03), and the initial concentration of the sample was 160 nM (final concentration 40 nM), 5
  • the sequence was diluted, 50 ⁇ L per well, and added to the cell culture plate.
  • Human IL-17A at a concentration of 20 ng/mL (final concentration 5 ng/mL) diluted to the same complete medium was added to the cell culture plate at 50 ⁇ L per well. Incubate for 1 hour at 37 ° C in a 5% CO 2 incubator.
  • the HFF-1 cells were then resuspended in complete medium and seeded into 96-well cell culture plates at 100 ⁇ L per well at 5000 cells per well.
  • the cells were incubated for 24 hours at 37 ° C in a 5% CO 2 incubator. After the completion of the incubation, the cell culture plate was centrifuged at 250 g for 5 minutes, and the culture supernatant was taken out, and the level of human IL-6 was measured by a human IL-6 ELISA kit (R&D systems, Cat. No. S6050) according to the instructions.
  • the anti-human IL-17A chimeric monoclonal antibody had stronger in vitro IL-17A neutralizing activity than secukinumab, and more potently inhibited human IL-17A-stimulated human IL-6 secreted by HFF-1 cells.
  • mice Female BALB/c mice, 6-8 weeks old, purchased from Beijing Huakang Biotechnology Co., Ltd.
  • Each group was given anti-human IL-17A chimeric monoclonal antibody, control monoclonal antibody secukinumab, three dose levels of 0.7 nmol/kg, 7 nmol/kg, 70 nmol/kg, intravenously, single administration.
  • human IL-17A was injected subcutaneously, 10 ⁇ g per mouse. Two hours later, blood was collected from the eyelids, and anticoagulation was not performed.
  • mice CXCL1 C-X-C Motif Chemokine Ligand, also known as KC
  • concentration of mouse CXCL1 in serum was determined using a mouse CXCL1 ELISA kit (RayBiotech, Cat. No. ELM-KC) according to the instructions.
  • the anti-human IL-17A chimeric monoclonal antibody was able to inhibit the level of CXCL1 secreted by human IL-17A-stimulated mice, and showed stronger activity than the control monoclonal antibody secukinumab.
  • mice Female SD rats, 6-8 weeks old, were purchased from Beijing Huakangkang Biotechnology Co., Ltd. One week after the rats were acclimated to the environment, they were randomized into groups of 3 each. Each group was given anti-human IL-17A chimeric monoclonal antibody, control monoclonal antibody secukinumab, the dose was 20 nmol/kg, intravenous injection, single administration. At 0 o'clock, 5 minutes after administration, 30 minutes, 1 hour, 3 hours, 6 hours, 10 hours, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours, 168 hours, 216 hours, 264 hours, 312 Blood was collected from the eyelids, and anticoagulation was not performed. The blood sample was placed at room temperature for 30 minutes to 1 hour. After coagulation, centrifuged at 3000 rpm for 10 minutes. The obtained serum samples were frozen at -80 ° C and stored for testing.
  • the concentration of anti-human IL-17A chimeric mAb in the serum, control monoclonal antibody secukinumab, was determined by ELISA. Briefly, human recombinant IL-17A protein was coated on a high adsorption ELISA plate overnight with a carbonate buffer solution of pH 9.6 at 4 °C. Wash with PBST. To prevent non-specific binding, the plates were blocked with PBS skim containing 5% skim milk powder and washed with PBST. Then, the test serum sample diluted with PBST containing 10% mixed rat serum and 1% BSA was added and incubated at 25 ° C for 1 hour, and the plate was washed with PBST.
  • Horseradish peroxidase-labeled anti-human IgG antibody (Chemicon, Cat. No. AP309P) diluted in PBST containing 5% skim milk powder was added, and the plate was washed with PBST at 25 ° C for 1 hour. Finally, color development was carried out using the colorimetric substrate TMB, and color development was carried out for 10 minutes at room temperature. Color development was terminated by the addition of 1 M H 2 SO 4 . The absorbance at 450 nm was read on a microplate reader.
  • the humanized form of the anti-IL-17 antibody was obtained according to the method of Leung et al. (1995, Molecule Immunol 32: 1413-27) d.
  • the humanized template that best matches its non-CDR region is selected in the Germline database.
  • the template for the heavy chain variable region is IGVH4-59*01, and the sequence is shown as SEQ ID NO:35.
  • the template for the light chain variable region is IGKV2-30*02 and the sequence is shown as SEQ ID NO:36.
  • the murine antibody CDR regions are grafted onto the selected humanized template, replacing the CDR regions of the human template.
  • the grafted humanized antibody heavy chain variable region is obtained as shown in SEQ ID NO: 37, the grafted humanized antibody light chain variable region, and the sequence is set forth in SEQ ID NO:38.
  • Back mutations were selected by sequence alignment of 9 loci, including 4 heavy chains, L4V, I49M, V68I, V72R, 5 light chains, D1I, V2I, F41Y, R51L, Y92F. The number of reversion sites was reduced, and different humanized sequences were constructed.
  • the heavy chain sequences and the light chain variable region sequences are shown in Table 3.
  • the heavy chain variable region (SEQ ID NO: 27-34) of the humanized anti-human IL-17A mAb was ligated to the human antibody IgG1 heavy chain constant region (SEQ ID NO: 10) to obtain the corresponding heavy chain, respectively. Full length sequence.
  • the light chain variable region (SEQ ID NO: 19-26) of the humanized anti-human IL-17A mAb was ligated to the constant region (SEQ ID NO: 9) of the human antibody Kappa light chain, respectively, to obtain a corresponding light
  • the full length sequence of the chain was combined with the full-length sequence of the light chain to obtain a full-length sequence of the humanized antibody, and the full-length sequence was digested with EcoRI and HindIII, and ligated into the X0GC vector.
  • the antigen binding activity of anti-human IL-17A humanized mAb was determined by ELISA.
  • Anti-human IL-17A humanized mAb samples in PBST containing 1% BSA and control were added to the sequence, and 100 ⁇ L was added to each well and incubated at 25 ° C for 1 hour. Wash PBST 5 times. Then, horseradish peroxidase-labeled anti-human IgG antibody (Chemicon, Cat. No. AP309P) diluted 1:2000 in PBST containing 1% BSA was added, 100 ⁇ L per well was added, and incubation was carried out for 1 hour at 25 °C. Wash PBST 5 times. The colorimetric substrate TMB was added at 100 ⁇ L/well and developed for 10 minutes at room temperature. Color development was stopped by adding 1 M H2SO4 at 100 ⁇ L/well. The absorbance at 450 nm was read on a microplate reader.
  • the anti-human IL-17A humanized monoclonal antibodies AS15799, AS15802, AS15803, AS15805, AS15810, AS15815, and AS15820 all bind human IL-17A and have high affinity activity.
  • Example 10 In vitro neutralizing activity of humanized anti-human IL-17A monoclonal antibody
  • the anti-human IL-17A antibody sample was diluted in DMEM (GIBCO, Cat. No. 11995-073) complete medium containing 10% FBS (Hyclone, Cat. No. SH30084.03), and the initial concentration of the sample was 160 nM (final concentration 40 nM), 5
  • the sequence was diluted, 50 ⁇ L per well, and added to the cell culture plate.
  • Human IL-17A at a concentration of 20 ng/mL (final concentration 5 ng/mL) diluted to the same complete medium was added to the cell culture plate at 50 ⁇ L per well. Incubate for 1 hour at 37 ° C in a 5% CO 2 incubator.
  • the HFF-1 cells were then resuspended in complete medium and seeded into 96-well cell culture plates at 100 ⁇ L per well at 5000 cells per well.
  • the cells were incubated for 24 hours at 37 ° C in a 5% CO 2 incubator. After the completion of the incubation, the cell culture plate was centrifuged at 250 g for 5 minutes, and the culture supernatant was taken out, and the level of human IL-6 was measured by a human IL-6 ELISA kit (R&D systems, Cat. No. S6050) according to the instructions.
  • Anti-human IL-17A humanized mAbs AS15799, AS15802, AS15803, AS15805, AS15810, AS15815, AS15820 have stronger in vitro IL-17A neutralizing activity than secukinumab, and stronger inhibition of human IL.
  • -17A stimulates human IL-6 secreted by HFF-1 cells.
  • Example 11 Determination of purity and thermal stability of humanized anti-human IL-17A monoclonal antibody by molecular sieve high performance liquid chromatography (SE-HPLC)
  • the denaturation temperature (Tm) of the humanized anti-human IL-17A monoclonal antibody was determined by differential scanning fluorimetry (DSF).
  • DSF is a method for detecting the thermal denaturation process of proteins in a sample by using the fluorescence intensity change of the fluorescent indicator to determine the protein denaturation temperature.
  • the reagent used was SYPRO Orange Protein Fluorescent Dye (Cat. No.: S5692, 5000 times concentration, solvent DMSO) was purchased from Sigma-Aldrich, USA.
  • the instrument was purchased from Applied Biosystems, Inc., USA for the AB 7500 Real Time PCR instrument.
  • the protein fluorescent dye was diluted 1:50 with sample buffer, and 1 ⁇ l of the diluted dye was mixed with 19 ⁇ l of the protein solution, and the final dilution of the fluorescent dye was 1:1000.
  • the sample was added to a 96-well plate, and each sample was set in three parallels. hole. The plate was sealed with an optical sealing plate and centrifuged at 1000 rpm for 2 minutes to remove air bubbles.
  • RT-PCR instrument settings are as follows: melting curve, using continuous mode, scanning temperature range is 25 ⁇ 99 ° C, heating rate is 1% (about 1 ° C / min), 25 ° C balance 2 min, collecting data during the heating process, reporting base
  • the group was selected to be ROX
  • the quenching group was selected to be None
  • the reaction volume was 20 ⁇ l.
  • the sample was assayed at a concentration of 1 mg/ml and the reference solution was sample buffer.
  • the Tm value of the humanized anti-human IL-17A monoclonal antibody prepared above was measured as shown in Table 5 below.
  • the humanized anti-human IL-17A monoclonal antibody has a good Tm value.
  • Example 13 Detection of Charge Isomers of Humanized Anti-Human IL-17A Monoclonal Antibody by Ion Exchange Chromatography (CEX)
  • the experimental results were processed with an Agilent HPLC Analyzer 1260 System Workstation and the area area percentage was calculated using the area normalization method.
  • the humanized anti-human IL-17A monoclonal antibody prepared above was subjected to CEX detection. In order to determine the chemical stability of these monoclonal antibodies, the above samples were placed under high temperature conditions of 40 ° C, and samples were taken at the 2nd and 4th weeks for CEX detection, and the change in the proportion of charge variants was observed. The results are shown in Table 6.
  • the humanized anti-human IL-17A antibody has a relatively low proportion of charge variants.
  • Example 14 Stability of humanized anti-human IL-17A monoclonal antibody under low pH virus inactivation conditions
  • test sample 200 ⁇ g was adjusted to pH 3.4 ⁇ 0.05 with 1 mol/L citric acid mother liquor, and the final concentration of the sample was 1 mg/mL. They were placed at room temperature and sampled at 0, 1, 2, 4 and 6 hours, respectively, and the pH was adjusted to 7.5 with 2 mol/LTris-HCl pH 9.5 stock solution. The samples were analyzed by the above SEC method, and the results are shown in Table 7.
  • the humanized anti-human IL-17A antibody can withstand low pH virus inactivation conditions for at least 6 hours with good stability.
  • mice Female SD rats, 6-8 weeks old, were purchased from Beijing Huakangkang Biotechnology Co., Ltd. One week after the rats were acclimated to the environment, they were randomized into groups of 3 each. Each group was given different anti-human IL-17A humanized monoclonal antibody and control antibody at a dose of 15 nmol/kg, subcutaneous injection, and single administration.
  • the antibody and functional fragment thereof provided by the present invention are capable of specifically binding to IL-17A, and are useful for preventing and/or treating diseases associated with overexpression and/or release of IL-17A, such as airway inflammation, asthma, Bronchial asthma, allergic asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, multiple sclerosis, system Sclerosing disease, systemic lupus erythematosus, lupus nephritis, scleroderma, ulcerative colitis, inflammatory bowel disease, uveitis, Helicobacter pylori-associated gastritis, osteoporosis, bone erosion, intraperitoneal abscess and adhesion , Addison's disease, gamma globulin deficiency, alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Optics & Photonics (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)

Abstract

一种能够特异性地结合IL-17A的抗体及其功能片段，所述抗体或其功能片段包括IL-17A嵌合抗体及其功能片段及IL-17A人源化抗体及其功能片段。

Description

一种能够特异性地结合IL-17A的抗体及其功能片段
本申请要求于2016年09月14日提交于中国专利局的申请号为CN201610827097.2、名称为“一种能够特异性地结合IL-17A的抗体及其功能片段”的中国专利申请的优先权，其全部内容通过引用结合在本申请中。
技术领域
本发明涉及医学生物技术和人源化抗体改造研究领域，具体而言，涉及一种能够特异性地结合IL-17A的抗体及其功能片段。
背景技术
白细胞介素17A(IL-17或IL-17A)是一种促炎性细胞因子，主要产生自Th17细胞，是IL-17家族中最具代表性的成员(Miossec P,Kolls JK.Nat.Rev.Drug.Discov.,2012,11:763-776)。IL-17A与其受体(IL-17RA)结合后，可诱导多种细胞(如成纤维细胞、上皮细胞和内皮细胞)表达炎症性细胞因子以及趋化因子，在机体免疫防御中发挥重要作用(Lin Y,Ritchea S,Logar A.Immunity,2009,31:799-810)。
然而，过高表达的IL-17A可引起诸多炎症疾病。如IL-17A作用于巨噬细胞，DC细胞，诱发IL-1，IL-6，TNF，CRP的高表达，导致炎症反应，参与银屑病和移植排斥的病理过程；IL-17A作用于内皮细胞，诱发IL-6，MMP，凝血因子的高表达，导致血管活化，参与再灌注损伤、血栓和动脉粥样硬化的病理过程；IL-17A作用于成纤维细胞，诱发IL-6，趋化因子，生长因子，MMP的高表达，导致基质破坏，参与多发性硬化症、克隆恩病的病理过程；IL-17A作用于成骨细胞和软骨细胞，诱导RANKL、MMP、破骨细胞生成、导致骨侵蚀、软骨损伤，参与风湿性关节炎、牙周病的病理过程(N Engl J Med.2009Aug27；361(9):888-98.Nat Rev Drug Discov.2012Oct；11(10):763-76.Semin Arthritis Rheum.2013Oct；43(2):158-70.Trends Mol Med.2016Mar；22(3):230-41.)。
IL-17A中和抗体可以抑制类风湿关节炎患者的滑膜组织高表达IL-17A，并降低重要炎症因子IL-6的产生(Chabaud M,Durand JM,Buchs N,et al.Arthritis Rheum.1999,42:963-70)。很多自身免疫疾病的动物模型实验证明，使用抗体中和IL-17A，可有效抑制炎症的病理发展(Lubberts E,Koenders MI,Oppers-Walgreen B,et al.Arthritis Rheum.，2004,50:650-659)。
目前，IL-17A相关抗体药物已经被批准上市，分别是Secukinumab(IL-17A靶向抗体)、Ixekizumab(IL-17A靶向抗体)，均用于治疗银屑病。然而，药物临床研究结果表明，对于某些慢性炎症疾病如类风湿性关节炎，这些药物并未表现出预期的治疗效果(Kellner H,Ther Adv Musculoskelet Dis.,2013,5:141-152)。
有鉴于此，特提出本发明。
发明内容
本发明是基于所获得的一株具有与人IL-17A蛋白特异性结合的亲本抗人IL-17A鼠单克隆抗体，通过克隆、鉴定与基因结构的分析，确定了其CDR区序列，构建了相应的嵌合抗体及人源化抗体，并建立了相应的真核细胞表达系统，生产纯化出了该嵌合抗体及人源化抗体。
为了实现本发明的上述目的，特采用以下技术方案：
一种能够特异性地结合IL-17A的抗体及其功能片段，所述抗体或抗体功能片段包含轻链和重链；
所述轻链具有由CDR-L1、CDR-L2、CDR-L3组成的轻链CDR；所述重链具有由CDR-H1、CDR-H2、CDR-H3组成的重链CDR；
所述CDR-L1、CDR-L2、CDR-L3的氨基酸序列分别如SEQ ID NO:1、2和3所示；所述CDR-H1、CDR-H2、CDR-H3的氨基酸序列分别如SEQ ID NO:4、5和6所示；
优选的，所述抗体或其功能片段包括IL-17A嵌合抗体及其功能片段及IL-17A人源化抗体及其功能片段。
也可理解为，所述抗体或其功能片段包括IL-17A嵌合抗体及其功能片段，或者是，所 述抗体或其功能片段包括IL-17A人源化抗体及其功能片段。
本领域公知，抗体的结合特异性及亲合力均主要由CDR序列决定，根据成熟、公知的现有各项技术可轻易地将非CDR区域的氨基酸序列改变而获得具有相类似的生物活性的变体。本发明涉及的具有与上述CDR序列完全相同的CDR序列的单克隆抗体变体，因其具有与本发明所述的人源化抗体完全相同的CDR序列，因此具有相类似的生物活性。
优选的，如上所述的抗体及其功能片段，所述抗体包含选自由人抗体IgG1、IgG2、IgG3、IgG4、IgA、IgM、IgE、IgD组成的组中的任意一种的恒定区的序列。
优选的，如上所述的抗体及其功能片段，所述功能片段包括选自由F(ab’)2、Fab’、Fab、Fv、scFv、双特异抗体和抗体最小识别单位组成的组中的一种或多种。
本发明所述的“功能片段”特别地指对于IL-17A具有与母体抗体相同特异性的抗体片段。除上述功能片段外，还包括半衰期已增加的任何片段。
scFv(sc＝单链)，双特异抗体(diabodies)。
这些功能片段通常具有与其来源抗体相同的结合特异性。本领域技术人员根据本发明说明中记载的内容推断，本发明的抗体片段可以通过比如酶消化的方法(包括胃蛋白酶或木瓜蛋白酶)和/或通过化学还原分裂二硫键的方法获得上述的功能片段。
抗体片段还可以通过也是本领域技术人员所知的重组遗传学技术或通过例如自动肽合成仪，比如Applied BioSystems等销售的自动肽合成仪，通过肽合成获得。
优选的，如上所述的抗体及其功能片段，所述IL-17A嵌合抗体及其功能片段的轻链可变区序列和重链可变区序列的氨基酸序列分别如SEQ ID NO:7和SEQ ID NO:8所示。
进一步优选的，如上所述的抗体及其功能片段，所述IL-17A嵌合抗体及其功能片段的轻链恒定区序列和重链恒定区序列的氨基酸序列分别如SEQ ID NO:9和SEQ ID NO:10所示。
优选的，如上所述的抗体及其功能片段，所述IL-17A人源化抗体及其功能片段的轻链骨架区包括FR-L1、FR-L2、FR-L3及FR-L4，重链骨架区包括FR-H1、FR-H2、FR-H3及FR-H4；
所述FR-L1、FR-L2、FR-L3及FR-L4的氨基酸序列依次如SEQ ID NO:11-14所示；
所述FR-H1、FR-H2、FR-H3及FR-H4的氨基酸序列依次如SEQ ID NO:15-18所示；
通常从鼠抗移植CDR到人源框架上，选择序列同源性高的人源框架会有一定的成功率。但是研究表明，许多CDR移植需要做回复突变，才能恢复一定的抗体活性。如何选择合适的人源框架是主要的瓶颈。
CDR是抗原结合的主要相关位点，但多数情况下FR(Framework region)对结合位点构象的影响明显，为获得高亲和力的人源化抗体，本发明选择了合适的FR区，并将相关FR残基需回复为原鼠源氨基酸或其他作用相同的人中可见的氨基酸。
优选的，所述FR-L1选自SEQ ID NO:11所示的氨基酸序列，或经过以下取代及其组合所得到的氨基序列：
第1个氨基酸D替换为I；
第2个氨基酸V替换为I；
所述FR-L2选自SEQ ID NO:12所示的氨基酸序列，或经过以下取代及其组合所得到的氨基序列：
第4个氨基酸F替换为Y；
第14个氨基酸R替换为L；
所述FR-L3选自SEQ ID NO:13所示的氨基酸序列，或经过以下取代及其组合所得到的氨基序列：
第35个氨基酸Y替换为F；
所述FR-L4选自SEQ ID NO:14所示的氨基酸序列；
所述FR-H1选自SEQ ID NO:15所示的氨基酸序列，或经过以下取代及其组合所得到 的氨基序列：
第4个氨基酸L替换为V；
所述FR-H2选自SEQ ID NO:16所示的氨基酸序列，或经过以下取代及其组合所得到的氨基序列：
第15个氨基酸I替换为M；
所述FR-H3选自SEQ ID NO:17所示的氨基酸序列，或经过以下取代及其组合所得到的氨基序列：
第2个氨基酸V替换为I；
第6个氨基酸V替换为R；
优选的，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：19-26任一项所示；
优选的，所述IL-17A人源化抗体及其功能片段的重链可变区序列如SEQ ID NO：27-34任一项所示；
更优选的，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：19所示；其对应的重链可变区序列如SEQ ID NO：27所示；
或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：20所示；其对应的重链可变区序列如SEQ ID NO：28所示；
或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：21所示；其对应的重链可变区序列如SEQ ID NO：29所示；
或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：22所示；其对应的重链可变区序列如SEQ ID NO：30所示；
或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：22所示；其对应的重链可变区序列如SEQ ID NO：31所示；
或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：23所示；其对应的重链可变区序列如SEQ ID NO：32所示；
或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：24所示；其对应的重链可变区序列如SEQ ID NO：33所示；
或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：25所示；其对应的重链可变区序列如SEQ ID NO：32所示；
或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：26所示；其对应的重链可变区序列如SEQ ID NO：34所示；
最优选的，所述IL-17A人源化抗体及其功能片段的轻链恒定区序列和重链恒定区序列的氨基酸序列分别如SEQ ID NO:9和SEQ ID NO:10所示。
所述IL-17A人源化抗体及其功能片段的轻链恒定区选自人抗体Kappa轻链恒定区，其氨基酸序列如SEQ ID NO:9所示；
所述IL-17A人源化抗体及其功能片段的重链恒定区选自人抗体IgG1重链恒定区，其氨基酸序列如SEQ ID NO:10所示。
需要说明的是，除本申请上述公开的氨基酸序列外，嵌合抗体和人源化抗体的产生可以由本领域技术人员通过任何已知的方法来实现，比如通过根据鼠抗体经测序的CDR而设计的重组人源化抗体，所述鼠抗体由来自免疫的小鼠或与骨髓瘤细胞相融合的其它物种的脾细胞的骨髓瘤细胞所分泌。所述免疫的动物可以包括转基因小鼠，其具有人类免疫球蛋白基因座，然后直接产生人类抗体。另外一个可能的实施方式可以包括使用噬菌体展示技术筛选文库。
一种分离的核酸分子，所述核酸分子选自如下核酸：
A)、DNA或RNA，其编码如上所述的抗体及其功能片段；
B)、与A)中定义的核酸互补的核酸。
一种载体，其包括如上所述的核酸分子。
本发明进一步包含至少一种编码如上所述的核酸分子的核构建体，优选载体，进一步优选为表达载体，比如质粒，在本申请的一个实施例中会介绍该载体的构建方法。
一种宿主细胞，其被如上所述的载体转化。
所述宿主细胞是真核细胞，比如哺乳动物细胞。
一种生产能够特异性地结合IL-17A的抗体及其功能片段的方法，包括如下步骤：
在培养基中和合适的培养条件下培养如上所述的宿主细胞；
从培养基中或从所培养的宿主细胞中回收如此产生的抗体及其功能片段。
一种组合物，所述组合物以如上所述的抗体和/或其功能片段、或它们与其他成分组成的化合物作为活性成分。
优选的，如上所述的组合物，所述抗体及其功能片段与至少一种诊断剂和/或治疗剂偶联以形成免疫偶联物。
优选的，如上所述的组合物，所述诊断剂选自由放射性核素、放射性造影剂、顺磁离子、金属、荧光标记、化学发光标记物、超声造影剂、光敏剂组成的组中的一种或多种；
优选的，所述放射性核素包括选自由110In、111In、177Lu、18F、52Fe、62Cu、64Cu、67Cu、67Ga、68Ga、86Y、90Y、89Zr、94mTc、94Tc、99mTc、120I、123I、124I、125I、131I、154-158Gd、32P、11C、13N、15O、186Re、188Re、51Mn、52mMn、55Co、72As、75Br、76Br、82mRb和83Sr组成的组中的一种或多种；
优选的，所述顺磁离子包括选自由铬(III)、锰(II)、铁(III)、铁(II)、钴(II)、镍(II)、铜(II)、钕(III)、钐(III)、镱(III)、钆(III)、钒(II)、铽(III)、镝(III)、钬(III)和铒(III)组成的组中的一种或多种；
优选的，所述荧光标记选自由Alexa 350、Alexa 405、Alexa 430、Alexa 488、Alexa 555、Alexa 647、AMCA、氨基吖啶、BODIPY 630/650、BODIPY 650/665、BODIPY-FL、BODIPY-R6G、BODIPY-TMR、BODIPY-TRX、5-羧基-4′，5′-二氯-2′，7′-二甲氧基荧光素、5-羧基-2′，4′，5′，7′-四氯荧光素、5-羧基荧光素、5-羧基罗丹明、6-羧基罗丹明、6-羧基四甲基罗丹明、Cascade Blue、Cy2、Cy3、Cy5、Cy7、6-FAM、丹磺酰氯、荧光素、HEX、6-JOE、NBD(7-硝基苯并-2-氧杂-1，3-二唑)、Oregon Green 488、Oregon Green 500、Oregon Green514、Pacific Blue、邻苯二甲酸、对苯二甲酸、间苯二甲酸、甲酚固紫、甲酚蓝紫、亮甲酚蓝、对氨基苯甲酸、赤藓红、酞菁、偶氮甲碱、花青、黄嘌呤、琥珀酰荧光素、稀土金属穴状化合物、三双吡啶基二胺铕、铕穴状化合物或螯合物、二胺、双花青苷、La Jolla蓝染料、别藻蓝蛋白、allococyanin B、藻蓝蛋白C、藻蓝蛋白R、硫胺、藻红青蛋白、藻红蛋白R、REG、罗丹明绿、罗丹明异硫氰酸酯、罗丹明红、ROX、TAMRA、TET、TRIT(四甲基罗丹明异硫醇)、四甲基罗丹明和德克萨斯红组成的组中的一种或多种。
优选的，如上所述的组合物，所述治疗剂选自由裸抗体、细胞毒素剂、药物、放射性核素、硼原子、免疫调节剂、抗凋亡试剂、光敏性治疗剂、免疫偶联物和寡核苷酸中组成的组的一种或多种；
优选的，所述药物选自由地塞米松、双氯芬酸、萘丁美酮、美洛昔康、塞来昔布、甲氨蝶呤、环磷酰胺、硫唑嘌呤、环孢素A和长春新碱组成的组中的一种或多种；
优选的，所述寡核苷酸选自由shRNA、miRNA和siRNA组成的组中的一种或多种；
优选的，所述免疫调节剂选自由细胞因子、趋化因子、干细胞生长因子、淋巴毒素、造血因子、集落刺激因子(CSF)、干扰素、促红细胞生成素、促血小板生成素、白介素(IL)、粒细胞-集落刺激因子(G-CSF)、粒细胞巨噬细胞-集落刺激因子(GM-CSF)和干细胞生长因子组成的组中的一种或多种；
其中，所述细胞因子优选选自由人生长激素、N-甲硫氨酰基人生长激素、牛生长激素、甲状旁腺激素、甲状腺素、胰岛素、胰岛素原、松弛素、松弛素原、促卵胞激素(FSH)、促甲状腺激素(TSH)、黄体生成素(LH)、肝生长因子、前列腺素、成纤维细胞生长因子、催乳 素、胎盘催乳素、OB蛋白、肿瘤坏死因子-α、肿瘤坏死因子-β、苗勒氏管抑制物质、小鼠促性腺激素相关肽、抑制素、激活素、血管内皮生长因子、整联蛋白、促血小板生成素(TPO)、NGF-β、血小板-生长因子、TGF-α、TGF-β、胰岛素样生长因子-I、胰岛素样生长因子-II、促红细胞生成素(EPO)、骨诱导因子、干扰素-α、干扰素-β、干扰素-γ、巨噬细胞-CSF(M-CSF)、IL-1、IL-1α、IL-2、IL-3、IL-4、IL-5、IL-6、IL-7、IL-8、IL-9、IL-10、IL-11、IL-12、IL-13、IL-14、IL-15、IL-16、IL-17、IL-18、IL-21、IL-25、LIF、FLT-3、血管抑素、血小板反应素、内皮抑素、肿瘤坏死因子和LT组成的组中的一种或多种。
所述趋化因子优选选自由RANTES、MCAF、MIP1-α、MIP1-β和IP-10组成的组中的一种或多种。
优选的，所述放射性核素选自由111In、111At、177Lu、211Bi、212Bi、213Bi、211At、62Cu、67Cu、90Y、125I、131I、133I、32P、33P、47Sc、111Ag、67Ga、153Sm、161Tb、152Dy、166Dy、161Ho、166Ho、186Re、188Re、189Re、211Pb、212Pb、223Ra、225Ac、77As、89Sr、99Mo、105Rh、149Pm、169Er、194Ir、58Co、80mBr、99mTc、103mRh、109Pt、119Sb、189mOs、192Ir、219Rn、215Po、221Fr、255Fm、11C、13N、15O、75Br、198Au、199Au、224Ac、77Br、113mIn、95Ru、97Ru、103Ru、105Ru、107Hg、203Hg、121mTe、122mTe、125mTe、165Tm、167Tm、168Tm、197Pt、109Pd、142Pr、143Pr、161Tb、57Co、58Co、51Cr、59Fe、75Se、201Tl、76Br和169Yb组成的组中的一种或多种。
如上所述的组合物在制备用于预防和/或治疗与IL-17A过量表达和/或释放相关的疾病的药物中的应用；
优选的，所述疾病选自由气道炎症、哮喘、支气管哮喘、过敏性哮喘、慢性阻塞性肺病、特发性肺纤维化、类风湿性关节炎、骨关节炎、强直性脊柱炎、银屑病关节炎、银屑病、多发性硬化症、系统性硬化症、系统性红斑狼疮、狼疮肾炎、硬皮病、溃疡性结肠炎、炎性肠病、葡萄膜炎、幽门螺杆菌相关性胃炎、骨质疏松、骨质侵蚀、腹膜内脓肿和粘连、艾迪生氏病、丙种球蛋白缺乏症、斑秃、乳糜泻、查加斯病，克隆氏病、同种异体移植排斥、白塞氏病、败血症、脓毒性或内毒素性休克以及缺血组成的组中的任意一种。
如上所述的能够特异性地结合IL-17A的抗体及其功能片段在制备用于预防和/或治疗与IL-17A过量表达和/或释放相关的疾病的药物中的应用。
一种备用于预防和/或治疗与IL-17A过量表达和/或释放相关的疾病的药物，所述药物含有如上所述的能够特异性地结合IL-17A的抗体及其功能片段以及医药学上可接受的载体；
或者，所述药物含有如上所述的组合物以及医药学上可接受的载体。
此处，术语“医药学上可接受的”指当化合物给人类施用时该化合物是生理上可接受的，且不会发生胃肠道紊乱、头晕等过敏反应或者类似这些过敏反应的全身过敏反应。
在本发明中，“医药学上可接受的载体”包括但不限于：粘合剂(如微晶纤维素、藻酸盐、明胶和聚乙烯吡咯烷酮)、填充剂(如淀粉、蔗糖、葡萄糖和无水乳酸)、崩解剂(如交联PVP、交联羧甲基淀粉钠、交联羧甲基纤维素钠、和低取代羟丙基纤维素)、润滑剂(硬脂酸镁、硬脂酸铝、滑石、聚乙二醇、苯甲酸钠)、润湿剂(如甘油)、表面活性剂(如十六烷醇)以及吸收促进剂、矫味剂、甜味剂、稀释剂、包衣剂等。
如上所述的疾病选自由气道炎症、哮喘、支气管哮喘、过敏性哮喘、慢性阻塞性肺病、特发性肺纤维化、类风湿性关节炎、骨关节炎、强直性脊柱炎、银屑病关节炎、银屑病、多发性硬化症、系统性硬化症、系统性红斑狼疮、狼疮肾炎、硬皮病、溃疡性结肠炎、炎性肠病、葡萄膜炎、幽门螺杆菌相关性胃炎、骨质疏松、骨质侵蚀、腹膜内脓肿和粘连、艾迪生氏病、丙种球蛋白缺乏症、斑秃、乳糜泻、查加斯病，克隆氏病、同种异体移植排斥、白塞氏病、败血症、脓毒性或内毒素性休克以及缺血组成的组中的任意一种。
一种预防和/或治疗与IL-17A过量表达和/或释放相关的疾病的方法，向个体施用如上所述的药物。
优选的，上述个体为人，进一步地，上述个体为需要预防和/或治疗与IL-17A过量表 达和/或释放相关的疾病的人。
如上所述的疾病选自由气道炎症、哮喘、支气管哮喘、过敏性哮喘、慢性阻塞性肺病、特发性肺纤维化、类风湿性关节炎、骨关节炎、强直性脊柱炎、银屑病关节炎、银屑病、多发性硬化症、系统性硬化症、系统性红斑狼疮、狼疮肾炎、硬皮病、溃疡性结肠炎、炎性肠病、葡萄膜炎、幽门螺杆菌相关性胃炎、骨质疏松、骨质侵蚀、腹膜内脓肿和粘连、艾迪生氏病、丙种球蛋白缺乏症、斑秃、乳糜泻、查加斯病，克隆氏病、同种异体移植排斥、白塞氏病、败血症、脓毒性或内毒素性休克以及缺血组成的组中的任意一种。
附图说明
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案，下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍，显而易见地，下面描述中的附图是本发明的一些实施方式，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下，还可以根据这些附图获得其他的附图。
图1为本发明实施例1中88号克隆分泌的单抗与人IL-17A的结合活性；
图2为本发明实施例1中88号克隆分泌的单抗对人IL-17A刺激HFF-1细胞分泌人IL-6的中和活性；
图3为本发明实施例4中抗人IL-17A嵌合单抗的种属特异性；
图4为本发明实施例4中抗人IL-17A嵌合单抗的结合特异性；
图5为本发明实施例5中抗人IL-17A嵌合单抗的体外中和活性；
图6为本发明实施例6中抗人IL-17A嵌合单抗的体内中和活性；
图7为本发明实施例7中单次静脉注射后的药时曲线；
图8为本发明实施例9中抗人IL-17A人源化单抗的抗原结合活性；
图9为本发明实施例10中抗人IL-17A人源化单抗的体外中和活性；
图10为本发明实施例15中单次皮下注射后的药时曲线。
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述，但是本领域技术人员将会理解，下列实施例仅用于说明本发明，而不应视为限制本发明的范围。实施例中未注明具体条件者，按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者，均为可以通过市售购买获得的常规产品。
实施例1 鼠源的抗人IL-17A单抗的制备
1.1、动物免疫
实验动物选用雌性BALB/c小鼠，6至8周龄，购自北京华阜康生物科技股份有限公司。小鼠适应环境一周后，开始免疫。重组人IL-17A蛋白使用大肠杆菌E.coli表达，收集包涵体后对包涵体进行变复性处理，获得可溶性IL-17A蛋白。首次免疫使用重组人IL-17A蛋白100μg与弗氏完全佐剂(Sigma-Aldrich，货号F5881)，充分混合形成乳液，于小鼠腹腔注射。两周之后，进行加强免疫。加强免疫使用重组人IL-17A蛋白50μg与弗氏不完全佐剂(Sigma-Aldrich，货号F5806)，充分混合形成乳液，于小鼠腹腔注射。每隔2周以同样的方法加强免疫，共加强免疫3次。末次免疫后第7天，从小鼠眼眶后静脉丛采血并离心分离血清，ELISA测定抗体效价。选择效价高的小鼠用来融合做杂交瘤。融合前三天，腹腔注射重组人IL-17A蛋白50μg，不含佐剂。融合当天，无菌取脾，制成单脾细胞悬液，以待融合。
1.2、杂交瘤细胞的制备
取对数生长的骨髓瘤细胞SP2/0，1000rpm离心5分钟，弃上清，用不完全DMEM培养液(Gibco，cat No.11965)混悬细胞后计数，取所需的细胞数，用不完全培养液洗涤2次。同时制备免疫脾细胞悬液，用不完全培养液洗涤2次。将骨髓瘤细胞与脾细胞按1∶10或1∶5的比例混合在一起，在50ml塑料离心管内用不完全培养液洗1次，1200rpm，8分钟。弃上清，用滴管吸净残留液体。在手掌上轻击离心管底，使沉淀细胞松散均匀；置 40℃水浴中预热。用1ml吸管在1分钟左右(最佳时间为45秒)加预热至40℃的45％PEG-4000(PH 8.0，Sigma，cat No.P7181)1ml，边加边轻轻搅拌(用吸管搅拌)，肉眼观察应有可见颗粒出现。用10ml吸管在90s内加20～30ml预热至37℃的不完全培养基以终止PEG作用；20～37℃静置10分钟。1000r/min离心5分钟，弃去上清。加入5ml HAT培养基(DMEM+HAT，Sigma，cat No.1H0262-10VL)，轻轻吹吸沉淀细胞(切记不能用力吹打，以免使融合在一起的细胞散开)，使其悬浮并混匀，然后补加HAT培养基至80-100ml(使脾细胞浓度为1～2×106/ml)。分装96孔细胞培养板，每孔0.1ml；分装24孔板，每孔1.0～1.5ml；然后将培养板置37℃，6％CO2培养箱内培养。一般铺6块96孔板。5天后用HAT培养基换出1/2培养基。再7～10天后用HT培养基(DMEM+HT，Sigma cat No.H0137-10VL)换出HAT培养基。经常观察杂交瘤细胞生长情况，待其长至孔底面积1/10以上时吸出上清供抗体检测。将阳性克隆的细胞扩大培养并冻存。
1.3、克隆筛选与鉴定
ELISA用于筛选杂交瘤培养上清液的抗人IL-17A抗体。用pH＝9.6的碳酸盐缓冲溶液在96孔高吸附酶标板上包被重组人IL-17A，包被浓度为1μg/mL，包被量为100μL每孔，包被在4℃过夜进行。PBST洗涤5次。用含1％BSA的PBST按300μL/孔封闭，25℃孵育1小时。PBST洗涤5次。加入培养上清液样品以及阳性对照，每孔加入100μL，25℃孵育1小时。PBST洗涤5次。然后加入1:10000稀释在含1％BSA的PBST里的辣根过氧化物酶标记的抗小鼠IgG抗体(Abcam，货号Ab7068)，每孔加入100μL，25℃孵育1小时。PBST洗涤5次。加入比色底物TMB，100μL/孔，室温显色10分钟。加入1M H2SO4，100μL/孔，终止显色。在酶标仪上读取450nm处的吸光度。根据OD450nm的强弱选取能够分泌抗人IL-17A结合抗体的阳性克隆。
细胞实验测定阳性克隆分泌的抗人IL-17A抗体是否是中和抗体。将抗人IL-17A抗体样品稀释于含10％FBS(Hyclone，货号SH30084.03)的DMEM(GIBCO，货号11995-073)完全培养基中，样品起始浓度为160nM(终浓度40nM)，5倍序列稀释，每孔50μL，加入细胞培养板中。再向细胞培养板中加入稀释于相同完全培养基的浓度为20ng/mL(终浓度5ng/mL)的人IL-17A，每孔50μL。在37℃，5％CO2培养箱中孵育1小时。然后将HFF-1细胞重悬在完全培养基中，接种到96孔细胞培养板内，100μL每孔，每孔5000个细胞。细胞在37℃，5％CO2培养箱中孵育培养24小时。孵育结束后，将细胞培养板250g离心5分钟，取出培养上清，用人IL-6ELISA试剂盒(R&D systems，货号S6050)，按说明书测定人IL-6的水平。能够抑制人IL-17A刺激HFF-1细胞分泌人IL-6的抗体，即是抗人IL-17A中和抗体。根据中和能力强弱选取能够分泌抗人IL-17A中和抗体的阳性克隆。
结果如图1所示，88号克隆具有强的人IL-17A结合活性，根据图2所示，88号克隆同时具有很强的人IL-17A中和活性。
1.4、单克隆抗体序列的测定
将筛选得到的同时具有抗原结合活性以及抗原中和活性的克隆，进行抗体DNA序列的测定。首先提取细胞mRNA，使用RNAprep Pure试剂盒(Tiangen，DP430)。步骤如下：悬浮细胞的收集1×107，300×g离心5min，将细胞收集到离心管中，仔细吸除所有培养基上清。立即进行裂解步骤。轻弹离心管底部，使细胞沉淀松散，加入适量裂解液RL600uL，旋涡震荡。将所有溶液转移至过滤柱CS上(过滤柱CS放在收集管中)，12，000rpm(～13，400×g)离心2min，收集滤液。向滤液中加入1倍体积70％乙醇(通常为350μl或600μl)，混匀，得到的溶液和沉淀一起转入吸附柱CR3中(吸附柱CR3放入收集管中)，12,000rpm(～13，400×g)离心30-60sec，倒掉收集管中的废液，将吸附柱CR3放回收集管中。向吸附柱CR3中加入350μl去蛋白液RW1，12,000rpm(～13，400×g)离心30～60sec，倒掉收集管中的废液，将吸附柱CR3放回收集管中。向吸附柱CR3中央加入80μl的DNase I工作液，室温放置15min。向吸附柱CR3中加入350μl去蛋白液RW1，12,000rpm(～13，400×g)离心30～60sec，倒掉收集管中的废液，将吸附柱CR3放回收集管中。向吸附柱CR3中加 入500μl漂洗液RW(使用前请先检查是否已加入乙醇)，室温静置2min，12,000rpm(～13，400×g)离心30～60sec，倒掉收集管中的废液，将吸附柱CR3放回收集管中。12,000rpm(～13，400×g)离心2min，倒掉废液。将吸附柱CR3置于室温放置数分钟，以彻底晾干吸附材料中残余的漂洗液。将吸附柱CR3转入一个新的RNase-Free离心管中，加入30～100μl RNase-Free ddH2O室温放置2min，12,000rpm(～13，400×g)离心2min，得到RNA溶液。
使用QuantScript RT试剂盒(Tiangen，KR103)合成cDNA第一链。步骤如下，将模板RNA在冰上解冻；引物、10×RT mix(其中包含RNasin和DTT)、Super pure dNTP混合液、RNase-Free ddH2O在室温(15～25℃)解冻，解冻后迅速置于冰上。使用前将每种溶液涡旋振荡混匀，简短离心以收集残留在管壁的液体。使用表1的引物配置逆转录体系混合液(天根生物Quant cDNA第一链合成试剂盒，货号KR103-04，10倍浓度反转录缓冲液2uL，超纯dNTP 2uL，随机引物2uL，逆转录酶1uL)，彻底混匀，涡旋振荡时间不超过5min。简短离心，并置于冰上，最后将模板RNA(50ng～2μg)加入到混合液中，彻底混匀，涡旋振荡时间不超过5sec，简短离心以收集管壁残留的液体。37℃孵育60min。将逆转录的产生的cDNA第一链用于后续PCR反应。
PCR反应使用的引物如表1所示。
表1 PCR引物
VH primer
F1:GAGGTGAAGCTGCAGGAGTCAGGACCTAGCCTGGTG
R1:AGGT(C/G)(A/C)AACTGCAG(C/G)AGTC(A/T)GG
R2:AGGT(C/G)(A/C)AGCTGCAG(C/G)AGTC(A/T)GG
R3:AGGT(C/G)CAGCTGCAG(C/G)AGTC(A/T)GG
R4:CCAGGGGCCAGTGGATAGACAAGCTTGGGTGTCGTTTT
F2:ATAGACAGATGGGGGTGTCGTTTTGGC
F3:CTTGACCAGGCATCCTAGAGTCA
F4:AGGGGCCAGTGGATAGACTGATGG
F5:AGGGACCAAGGGATAGACAGATGG
R5:(G/C)A(A/G)GT(A/T/C/G)(A/C)AGCTG(G/C)AG(G/C)AGTC
R6:(G/C)A(A/G)GT(A/T/C/G)(A/C)AGCTG(G/C)AG(G/C)AGTC(A/T)GG
VL primer
R1:GGTGATATCGTGAT(A/G)AC(C/A)CA(G/A)GATGAACTCTC
R2:GGTGATATC(A/T)TG(A/C)TGACCCAA(A/T)CTCCACTCTC
R3:GGTGATATCGT(G/T)CTCAC(C/T)CA(A/G)TCTCCAGCAAT
F1:GGGAAGATGGATCCAGTTGGTGCAGCATCAGC
F2:GGATACAGTTGGTGCAGCATC
R4:GA(C/T)ATTGTG(A/C)T(G/C)AC(A/C)CA(A/G)(A/T)CT(A/C)CA
使用引物时，VH primer中的任一上游引物可与任一下游引物配合使用；同理在VL primer中的任一上游引物也可与任一下游引物配合使用。将PCR扩增得到的目的条带克隆到pGEM-T载体中。挑取单克隆进行DNA测序。
实施例2 嵌合的抗人IL-17A单抗的制备
经过PCR扩增得到抗体轻链可变区氨基酸序列如SEQ ID NO:7所示，抗体重链可变区氨基酸序列如SEQ ID NO:8所示。根据小鼠可变区序列排除骨架区序列后即可得到其互补决定区序列；其中轻链的三个互补决定区CDR-L1、CDR-L2、CDR-L3的氨基酸序列分别如SEQ ID NO:1、2和3所示；重链的三个互补决定区CDR-H1、CDR-H2、CDR-H3的氨基酸序列分别如SEQ ID NO:4、5和6所示。抗体轻链恒定区氨基酸序列如SEQ ID NO:9所示，抗体重链恒定区氨基酸序列如SEQ ID NO:10所示。将编码上述抗体轻链(轻链全长序列为将SEQ ID NO:7和SEQ ID NO:9连接即得)及重链(重链全长序列为将SEQ ID NO:8和SEQ ID NO:10连接即得)的核酸序列克隆到真核表达载体X0GC中(其中抗体轻链全长核酸序列如SEQ ID NO：23所示，抗体重链全长核酸序列如SEQ ID NO：24所示)，再将表达载体转染293F细胞系(FreeStyleTM 293-F Cells，货号R79007，invitrogen)。转染前一天接种细胞，转染当天将细胞离心收集细胞，将细胞重悬于新鲜的FreeStyleTM 293表达培养基(FreeStyleTM 293Expression Medium，货号12338001，Gibco)中，细胞密度为200×105细胞/mL。按照转染体积加入质粒，终浓度为36.67ug/mL，轻轻混匀；然后加入线性PEI(聚乙烯亚胺，线形，M.W.25000，货号43896，Alfa Aesar)，终浓度为55ug/mL，轻轻混匀。之后放入细胞培养箱，120rpm摇床37℃培养1小时。之后加入19倍转染体积的新鲜培养基。继续120rpm摇床37℃培养。离心收集转染5～6天的细胞培养上清。
实施例3 嵌合的抗人IL-17A单抗与人IL-17A结合的动力学常数
用Biacore3000仪器来检测抗人IL-17A嵌合单抗与其抗原人IL-17A结合的动力学常数。该仪器利用光学的表面等离子体共振技术来检测偶联包被在生物芯片上的分子与待测分子之间的结合和解离。所用的主要试剂为氨基偶联试剂盒(GE Healthcare，BR-1000-14)和CM5芯片(GE Healthcare，BR-1000-50)。实验过程简要的说，将人IL-17A溶于pH＝5.0的醋酸钠缓冲溶液中，10μL/min的速度注入偶联到CM芯片上，并用1M乙醇胺以10μL/min的速度注入来进行封闭。在结合阶段，将不同浓度的抗人IL-17A嵌合单抗以及对照分别以30μL/min的速度注入180秒，在解离阶段，用PBS缓冲溶液以30μL/min的速度注入600秒。再生条件为10mM甘氨酸盐溶液，pH 2.0。结合动力学常数和解离动力学常数通过Biacore3000control software来进行分析计算。抗人IL-17A嵌合抗体的结合动力学常数、解离动力学常数和解离平衡常数见表2。与secukinumab相比，抗人IL-17A单抗具有更小的解离平衡常数，更强的亲和力，尤其结合IL-17A抗原后能更长时间的维持结合状态，更难解离，这对其生物学功能是很有利的。
表2.抗人IL-17A嵌合抗体与人IL-17A结合的动力学常数
检测样品 Kon(1/Ms) Koff(1/s) KD(nM)
Secukinumab 2.52E+05 7.96E-05 0.32
抗人IL-17A嵌合抗体 5.41E+04 1.49E-06 0.03
实施例4 嵌合的抗人IL-17A单抗的种属特异性和结合特异性
用ELISA测定抗人IL-17A嵌合单抗的种属特异性。用pH＝9.6的碳酸盐缓冲溶液在96孔高吸附酶标板上包被重组人IL-17A，猴IL-17A，大鼠IL-17A和小鼠IL-17A，均购自义翘神州，包被浓度为1μg/mL，包被量为100μL每孔，包被在4℃过夜进行。PBST洗涤5次。用含1％BSA的PBST按300μL/孔封闭，25℃孵育1小时。PBST洗涤5次。加入序列稀释在含1％BSA的PBST里的抗人IL-17A嵌合单抗样品以及对照，每孔加入100μL，25℃孵育1小时。PBST洗涤5次。然后加入1:2000稀释在含1％BSA的PBST里的辣根过氧化物酶标记的抗人IgG抗体(Chemicon，货号AP309P)，每孔加入100μL，25℃孵育1小时。PBST洗涤5次。加入比色底物TMB，100μL/孔，室温显色10分钟。加入1MH2SO4，100μL/孔，终止显色。在酶标仪上读取450nm处的吸光度。
用ELISA测定抗人IL-17A嵌合单抗的结合特异性。用pH＝9.6的碳酸盐缓冲溶液在96 孔高吸附酶标板上包被重组人IL-17A，IL-17B，IL-17C，IL-17D，IL-17E，IL-17F，IL-1，IL-2，IL-6，IL-8，IL-21，IL-22，IL-23，IFN-g和TNFa(购自北京义翘神州或者R&D systems)，包被浓度为1μg/mL，包被量为100μL每孔，包被在4℃过夜进行。PBST洗涤5次。用含1％BSA的PBST按300μL/孔封闭，25℃孵育1小时。PBST洗涤5次。加入稀释在含1％BSA的PBST里的抗人IL-17A嵌合单抗样品以及对照，每孔加入100μL，25℃孵育1小时。PBST洗涤5次。然后加入1:2000稀释在含1％BSA的PBST里的辣根过氧化物酶标记的抗人IgG抗体(Chemicon，货号AP309P)，每孔加入100μL，25℃孵育1小时。PBST洗涤5次。加入比色底物TMB，100μL/孔，室温显色10分钟。加入1M H2SO4，100μL/孔，终止显色。在酶标仪上读取450nm处的吸光度。
结果如图3所示，抗人IL-17A嵌合单抗可以结合人，猴子IL-17A，但不与大鼠，小鼠IL-17A结合，具有种属特异性。同时，如图4所示，抗人IL-17A嵌合单抗还具有很强的结合特异性，仅与IL-17A结合，不与IL-17家族的其他细胞因子，以及不相关细胞因子结合。
实施例5 嵌合的抗人IL-17A单抗的体外中和活性
将抗人IL-17A抗体样品稀释于含10％FBS(Hyclone，货号SH30084.03)的DMEM(GIBCO，货号11995-073)完全培养基中，样品起始浓度为160nM(终浓度40nM)，5倍序列稀释，每孔50μL，加入细胞培养板中。再向细胞培养板中加入稀释于相同完全培养基的浓度为20ng/mL(终浓度5ng/mL)的人IL-17A，每孔50μL。在37℃，5％CO2培养箱中孵育1小时。然后将HFF-1细胞重悬在完全培养基中，接种到96孔细胞培养板内，100μL每孔，每孔5000个细胞。细胞在37℃，5％CO2培养箱中孵育培养24小时。孵育结束后，将细胞培养板250g离心5分钟，取出培养上清，用人IL-6ELISA试剂盒(R&D systems，货号S6050)，按说明书测定人IL-6的水平。
结果如图5所示，抗人IL-17A嵌合单抗具有比secukinumab更强的体外IL-17A中和活性，更强的抑制人IL-17A刺激HFF-1细胞分泌的人IL-6。
实施例6 嵌合的抗人IL-17A单抗的体内中和活性
实验材料选用雌性BALB/c小鼠，6-8周龄，购自北京华阜康生物科技股份有限公司。小鼠适应环境一周后，随机分组，每组6只。各组分别给予抗人IL-17A嵌合单抗，对照单抗secukinumab，三个剂量水平0.7nmol/kg，7nmol/kg，70nmol/kg，静脉注射，单次给药。在给药1小时候，皮下注射人IL-17A，每只小鼠10μg。再2小时之后，眼眶采血，不予抗凝，室温放置血样30分钟至1个小时，待凝血后，3000rpm离心10分钟，得到血清样品。采用小鼠CXCL1ELISA试剂盒(RayBiotech，货号ELM-KC)，按说明书测定血清中小鼠CXCL1(C-X-C Motif Chemokine Ligand，又名KC)的浓度。
结果如图6所示，抗人IL-17A嵌合单抗能够抑制人IL-17A刺激小鼠分泌的CXCL1的水平，比对照单抗secukinumab显示出了更强的活性。
实施例7 嵌合的抗人IL-17A单抗的在大鼠体内的药代动力学研究
实验材料选用雌性SD大鼠，6-8周龄，购自北京华阜康生物科技股份有限公司。大鼠适应环境一周后，随机分组，每组3只。各组分别给予抗人IL-17A嵌合单抗，对照单抗secukinumab，剂量均为20nmol/kg，静脉注射，单次给药。在0点，给药后5分钟，30分钟，1小时、3小时、6小时、10小时、24小时、48小时、72小时、96小时、120小时、168小时、216小时、264小时、312小时眼眶采血，不予抗凝，室温放置血样30分钟至1个小时，待凝血后，3000rpm离心10分钟，得到的血清样品冷冻于-80℃保存，待测。
ELISA测定血清中抗人IL-17A嵌合单抗，对照单抗secukinumab的浓度。简要的说，用pH＝9.6的碳酸盐缓冲溶液4℃过夜包被人重组IL-17A蛋白于高吸附酶标板上。PBST洗涤。为了防止非特异性结合，用含5％脱脂奶粉的PBST封闭该板，PBST洗涤。然后加入用含10％混合大鼠血清、1％BSA的PBST稀释的待测血清样品孵育，25℃，1小时，PBST洗涤该板。加入稀释于含5％脱脂奶粉的PBST中的辣根过氧化物酶标记的抗人IgG抗体 (Chemicon，货号AP309P)，25℃，1小时，PBST洗涤该板。最后使用比色底物TMB进行显色，室温显色10分钟。加入1M H2SO4，终止显色。在酶标仪上读取450nm处的吸光度。
结果如图7所示，单次静脉注射的剂量为20nmol/kg的抗人IL-17A嵌合单抗，对照单抗secukinumab，在大鼠体内显示出了相似的药时曲线和药代动力学特征。抗人IL-17A嵌合单抗的药代参数如下：半衰期t1/2为458小时；药时曲线下面积AUClast为44286nM.hr；估算零浓度C0为413nM；表观分布容积Vd为115mL/Kg；清除率CL为0.17mL/hr/kg；平均驻留时间MRTlast为140小时。
实施例8 人源化的抗人IL-17A单抗的制备
人源化形式的抗IL-17抗体是根据Leung等人(1995，Molecule Immunol 32:1413-27)d的方法获得。
在Germline数据库中选取与其非CDR区匹配最好的人源化模板。其中重链可变区的模板为IGVH4-59*01，序列如SEQ ID NO:35所示。轻链可变区的模板为IGKV2-30*02，序列如SEQ ID NO:36所示。将鼠源抗体CDR区移植到选择的人源化模板上，替换人模板的CDR区。得到移植的人源化抗体重链可变区，序列如SEQ ID NO:37所示，移植的人源化抗体轻链可变区，序列如SEQ ID NO:38所示。通过序列比对选择9个位点进行回复突变，其中重链4个，L4V，I49M，V68I，V72R，轻链5个，D1I，V2I，F41Y，R51L，Y92F。减少回复突变位点数量，构建不同的人源化序列，重链序列及轻链可变区序列如表3所示。将人源化的抗人IL-17A单抗的重链可变区(SEQ ID NO：27-34)与人抗体IgG1重链恒定区(SEQ ID NO:10)连接，分别得到对应的重链全长序列。将人源化的抗人IL-17A单抗的轻链可变区(SEQ ID NO：19-26)与人抗体Kappa轻链的恒定区(SEQ ID NO:9)连接，分别得到对应的轻链全长序列。将重链全长序列与轻链全长序列组合得到人源化抗体全长序列，将全长序列通过EcoRI和HindIII酶切，连接入X0GC载体中。
表3.抗人IL-17A人源化抗体的重链可变区和轻链可变区序列
Figure PCTCN2017101083-appb-000001
实施例9.人源化的抗人IL-17A单抗的抗原结合活性
用ELISA测定抗人IL-17A人源化单抗的抗原结合活性。用pH＝9.6的碳酸盐缓冲溶液在96孔高吸附酶标板上包被重组人IL-17A，购自义翘神州，包被浓度为1μg/mL，包被量为100μL每孔，包被在4℃过夜进行。PBST洗涤5次。用含1％BSA的PBST按300μL/孔封闭，25℃孵育1小时。PBST洗涤5次。加入序列稀释在含1％BSA的PBST里的抗人IL-17A人源化单抗样品以及对照，每孔加入100μL，25℃孵育1小时。PBST洗涤5次。 然后加入1:2000稀释在含1％BSA的PBST里的辣根过氧化物酶标记的抗人IgG抗体(Chemicon，货号AP309P)，每孔加入100μL，25℃孵育1小时。PBST洗涤5次。加入比色底物TMB，100μL/孔，室温显色10分钟。加入1M H2SO4，100μL/孔，终止显色。在酶标仪上读取450nm处的吸光度。
结果如图8所示，抗人IL-17A人源化单抗AS15799，AS15802，AS15803，AS15805，AS15810，AS15815，AS15820均可以结合人IL-17A，具有很高的亲和活性。
实施例10.人源化的抗人IL-17A单抗的体外中和活性
将抗人IL-17A抗体样品稀释于含10％FBS(Hyclone，货号SH30084.03)的DMEM(GIBCO，货号11995-073)完全培养基中，样品起始浓度为160nM(终浓度40nM)，5倍序列稀释，每孔50μL，加入细胞培养板中。再向细胞培养板中加入稀释于相同完全培养基的浓度为20ng/mL(终浓度5ng/mL)的人IL-17A，每孔50μL。在37℃，5％CO2培养箱中孵育1小时。然后将HFF-1细胞重悬在完全培养基中，接种到96孔细胞培养板内，100μL每孔，每孔5000个细胞。细胞在37℃，5％CO2培养箱中孵育培养24小时。孵育结束后，将细胞培养板250g离心5分钟，取出培养上清，用人IL-6ELISA试剂盒(R&D systems，货号S6050)，按说明书测定人IL-6的水平。
结果如图9所示，抗人IL-17A人源化单抗AS15799，AS15802，AS15803，AS15805，AS15810，AS15815，AS15820具有比secukinumab更强的体外IL-17A中和活性，更强的抑制人IL-17A刺激HFF-1细胞分泌的人IL-6。
实施例11.分子筛高效液相色谱法(SE-HPLC)检测人源化的抗人IL-17A单抗的纯度及其热稳定性
选用的TSKgel SuperSW3000色谱柱(货号：0018675)；流动相为0.1mol/L磷酸盐缓冲液
(NaH2PO4-Na2HPO4)，0.1mol/L硫酸钠缓冲液，pH 6.7；流速为0.35mL/min；柱温为25℃；样品池温度：4℃；检测波长280nm；用样品缓冲液稀释样品至1mg/mL，上样量为5μg。用Agilent高效液相分析仪1260系统工作站对实验结果进行数据处理，用面积归一化法计算主峰比例即为纯度。对上述制备的人源化的抗人IL-17A单抗进行了SE-HPLC纯度检测。为了确定这些单抗的热稳定性，将上述样品置于40℃高温条件下，在第2周和第4周分别取样进行SE-HPLC检测以观察热稳定性，结果如下表4所示。人源化的抗人IL-17A单抗均显示很好的热稳定性。
表4.SE-HPLC检测人源化的抗人IL-17A单抗在40℃条件下的热稳定性
Figure PCTCN2017101083-appb-000002
实施例12.人源化的抗人IL-17A单抗Tm值的测定
采用差示扫描荧光法(Differential scanning fluorimetry，DSF)测定人源化的抗人IL-17A单抗的变性温度(Tm)。DSF是一种利用荧光指示剂的荧光强度改变来检测样品中蛋白热变性过程的方法，实现蛋白变性温度的测定。选用的试剂为SYPRO Orange蛋白质荧光染料(货号：S5692，5000倍浓度，溶剂为DMSO)购自美国Sigma-Aldrich公司。仪器为AB 7500Real Time PCR仪购自美国Applied Biosystems公司。将蛋白质荧光染料按1：50用样品缓冲液进行稀释，取1μl稀释后染料分别与19μl蛋白溶液混合，荧光染料终稀释度为1：1000，加入96孔板中，每个样品设三个平行孔。用光学封板膜封板，1000rpm离心2min，去除气泡。RT-PCR仪器设置如下：熔解曲线，采用连续模式，扫描温度范围为25～99℃，升温速率为1％(约1℃/min)，25℃平衡2min，在升温过程中采集数据，报告基团选择 ROX，淬灭基团选择None，反应体积20μl。样品测定浓度为1mg/ml，参比溶液为样品缓冲液。采用Protein Thermal ShiftTM Software v1.3软件绘制荧光曲线及其一阶导数图。DSF试验中，通常以蛋白第1个转变中点温度作为蛋白制剂热稳定性的变性温度。如下表5所示，对上述制备的人源化的抗人IL-17A单抗进行了Tm值测定。人源化的抗人IL-17A单抗均有很好的Tm值。
表5.人源化的抗人IL-17A单抗的Tm值
人源化的抗人IL-17A单抗 Tm值
AS15802 67.2℃
AS15803 68.3℃
AS15810 67.9℃
AS15815 69.3℃
AS15820 67.7℃
实施例13.离子交换色谱法(CEX)检测人源化的抗人IL-17A单抗的电荷异构体
采用阳离子交换色谱柱MabPac SCX-10，4mm×250mm(货号：78655)，以20mmol/L吗啉乙磺酸(2-(N-Morpholino)ethanesulfonic acid，MES)(pH5.6)和60mmol/L氯化钠为流动相A；以20mmol/L MES(pH5.6)和300mmol/L氯化钠为流动相B；流速为0.5mL/min；柱温为25℃；样品池温度：4℃；检测波长为280nm；样品上样量为50μl(1mg/mL)；洗脱为5～50％线性梯度运行60分钟。用Agilent高效液相分析仪1260系统工作站对实验结果进行数据处理，用面积归一化法计算峰面积百分比。对上述制备的人源化的抗人IL-17A单抗进行了CEX检测。为了确定这些单抗的化学稳定性，将上述样品置于40℃高温条件下，在第2周和第4周分别取样进行CEX检测，观察电荷变异体比例的变化，结果如表6所示。人源化的抗人IL-17A抗体，电荷变异体的比例变化均比较低。
表6.CEX检测人源化的抗人IL-17A单抗在40℃条件下电荷变异体的变化
Figure PCTCN2017101083-appb-000003
实施例14.人源化的抗人IL-17A单抗在低pH病毒灭活条件下的稳定性
取测试样品200μg分别用1mol/L柠檬酸母液将pH调整到3.4±0.05，样品最终浓度为1mg/mL。室温下放置，分别在0、1、2、4及6小时取样，用2mol/LTris-HCl pH 9.5母液将pH调至7.5。样品用上述SEC方法进行分析，结果如表7所示。人源化的抗人IL-17A抗体可以耐受至少6小时的低pH病毒灭活条件，稳定性良好。
表7.SE-HPLC检测人源化的抗人IL-17A单抗在低pH条件下的稳定性
Figure PCTCN2017101083-appb-000004
实施例15.人源化的抗人IL-17A单抗的在大鼠体内的药代动力学研究
实验材料选用雌性SD大鼠，6-8周龄，购自北京华阜康生物科技股份有限公司。大鼠适应环境一周后，随机分组，每组3只。各组分别给予不同的抗人IL-17A人源化单抗、对照抗体，剂量均为15nmol/kg，皮下注射，单次给药。在0点，给药后1小时、4小时、8小时、24小时、48小时、72小时、96小时、120小时、168小时、216小时、264小时、312小时、360小时、408小时、480小时眼眶采血，不予抗凝，室温放置血样30分钟至1 个小时，待凝血后，3000rpm离心10分钟，得到的血清样品冷冻于-80℃保存，待测。
ELISA测定血清中抗人IL-17A人源化单抗、对照抗体的浓度。简要的说，用pH＝9.6的碳酸盐缓冲溶液4℃过夜包被人重组IL-17A蛋白于高吸附酶标板上。PBST洗涤。为了防止非特异性结合，用含5％脱脂奶粉的PBST封闭该板，PBST洗涤。然后加入用含10％混合大鼠血清、1％BSA的PBST稀释的待测血清样品孵育，25℃，1小时，PBST洗涤该板。加入稀释于含5％脱脂奶粉的PBST中的辣根过氧化物酶标记的抗人IgG抗体(Chemicon，货号AP309P)，25℃，1小时，PBST洗涤该板。最后使用比色底物TMB进行显色，室温显色10分钟。加入1M H2SO4，终止显色。在酶标仪上读取450nm处的吸光度。
结果如图10所示，单次皮下注射的剂量为15nmol/kg的不同的抗人IL-17A人源化单抗，对照单抗secukinumab，对照单抗ixekizumab，在大鼠体内显示出了相似的药时曲线和药代动力学特征。
最后应说明的是：以上各实施例仅用以说明本发明的技术方案，而非对其限制；尽管参照前述各实施例对本发明进行了详细的说明，但本领域的普通技术人员应当理解：其依然可以对前述各实施例所记载的技术方案进行修改，或者对其中部分或者全部技术特征进行等同替换；而这些修改或者替换，并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
工业实用性：本发明提供的抗体及其功能片段能够特异性地结合IL-17A，可用于预防和/或治疗与IL-17A过量表达和/或释放相关的疾病，例如气道炎症、哮喘、支气管哮喘、过敏性哮喘、慢性阻塞性肺病、特发性肺纤维化、类风湿性关节炎、骨关节炎、强直性脊柱炎、银屑病关节炎、银屑病、多发性硬化症、系统性硬化症、系统性红斑狼疮、狼疮肾炎、硬皮病、溃疡性结肠炎、炎性肠病、葡萄膜炎、幽门螺杆菌相关性胃炎、骨质疏松、骨质侵蚀、腹膜内脓肿和粘连、艾迪生氏病、丙种球蛋白缺乏症、斑秃、乳糜泻、查加斯病、克隆氏病、同种异体移植排斥、白塞氏病、败血症、脓毒性或内毒素性休克以及缺血等。

Claims (14)

  1. 一种能够特异性地结合IL-17A的抗体及其功能片段，其特征在于，所述抗体或抗体功能片段包含轻链和重链；
    所述轻链具有由CDR-L1、CDR-L2、CDR-L3组成的轻链CDR；所述重链具有由CDR-H1、CDR-H2、CDR-H3组成的重链CDR；
    所述CDR-L1、CDR-L2、CDR-L3的氨基酸序列分别如SEQ ID NO：1、2和3所示；所述CDR-H1、CDR-H2、CDR-H3的氨基酸序列分别如SEQ ID NO：4、5和6所示；
    优选的，所述抗体或其功能片段包括IL-17A嵌合抗体及其功能片段及IL-17A人源化抗体及其功能片段。
  2. 根据权利要求1所述的抗体及其抗体功能片段，其特征在于，所述抗体包含选自由人抗体IgG1、IgG2、IgG3、IgG4、IgA、IgM、IgE以及IgD组成的组中的任意一种的恒定区的序列。
  3. 根据权利要求1或2所述的抗体及其功能片段，其特征在于，所述功能片段包括选自由F(ab’)2、Fab’、Fab、Fv、scFv、双特异抗体和抗体最小识别单位组成的组中的一种或多种。
  4. 根据权利要求1-3任一项所述的抗体及其功能片段，其特征在于，所述IL-17A嵌合抗体及其功能片段的轻链可变区序列和重链可变区序列的氨基酸序列分别如SEQ ID NO：7和SEQ ID NO：8所示；
    优选的，所述IL-17A嵌合抗体及其功能片段的轻链恒定区序列和重链恒定区序列的氨基酸序列分别如SEQ ID NO：9和SEQ ID NO：10所示。
  5. 根据权利要求1-3任一项所述的抗体及其功能片段，其特征在于，
    所述IL-17A人源化抗体及其功能片段的轻链骨架区包括FR-L1、FR-L2、FR-L3及FR-L4，重链骨架区包括FR-H1、FR-H2、FR-H3及FR-H4；
    所述FR-L1选自SEQ ID NO:11所示的氨基酸序列，或经过以下取代及其组合所得到的氨基序列：
    第1个氨基酸D替换为I；
    第2个氨基酸V替换为I；
    所述FR-L2选自SEQ ID NO:12所示的氨基酸序列，或经过以下取代及其组合所得到的氨基序列：
    第4个氨基酸F替换为Y；
    第14个氨基酸R替换为L；
    所述FR-L3选自SEQ ID NO:13所示的氨基酸序列，或经过以下取代及其组合所得到的氨基序列：
    第35个氨基酸Y替换为F；
    所述FR-L4选自SEQ ID NO:14所示的氨基酸序列；
    所述FR-H1选自SEQ ID NO:15所示的氨基酸序列，或经过以下取代及其组合所得到的氨基序列：
    第4个氨基酸L替换为V；
    所述FR-H2选自SEQ ID NO:16所示的氨基酸序列，或经过以下取代及其组合所得到的氨基序列：
    第15个氨基酸I替换为M；
    所述FR-H3选自SEQ ID NO:17所示的氨基酸序列，或经过以下取代及其组合所得到的氨基序列：
    第2个氨基酸V替换为I；
    第6个氨基酸V替换为R；
    所述FR-H4选自SEQ ID NO:18所示的氨基选序列；
    优选的，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：19-26任一项所示；
    优选的，所述IL-17A人源化抗体及其功能片段的重链可变区序列如SEQ ID NO：27-34任一项所示；
    更优选的，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：19所示；其对应的重链可变区序列如SEQ ID NO：27所示；
    或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：20所示；其对应的重链可变区序列如SEQ ID NO：28所示；
    或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：21所示；其对应的重链可变区序列如SEQ ID NO：29所示；
    或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：22所示；其对应的重链可变区序列如SEQ ID NO：30所示；
    或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：22所示；其对应的重链可变区序列如SEQ ID NO：31所示；
    或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：23所示；其对应的重链可变区序列如SEQ ID NO：32所示；
    或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：24所示；其对应的重链可变区序列如SEQ ID NO：33所示；
    或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：25所示；其对应的重链可变区序列如SEQ ID NO：32所示；
    或，所述IL-17A人源化抗体及其功能片段的轻链可变区序列如SEQ ID NO：26所示；其对应的重链可变区序列如SEQ ID NO：34所示；
    更优选的，所述IL-17A人源化抗体及其功能片段的轻链恒定区序列和重链恒定区序列的氨基酸序列分别如SEQ ID NO:9和SEQ ID NO:10所示。
  6. 一种分离的核酸分子，其特征在于，所述核酸分子选自如下核酸：
    A)、DNA或RNA，其编码权利要求1～5任一项所述的抗体及其功能片段；
    B)、与A)中定义的核酸互补的核酸。
  7. 一种组合物，其特征在于，所述组合物以权利要求1～5任一项所述的抗体和/或其功能片段、或它们与其他成分组成的化合物作为活性成分。
  8. 根据权利要求7所述的组合物，其特征在于，所述抗体及其功能片段与至少一种诊断剂和/或治疗剂偶联以形成免疫偶联物。
  9. 根据权利要求8所述的组合物，其特征在于，所述诊断剂选自由放射性核素、放射性造影剂、顺磁离子、金属、荧光标记、化学发光标记物、超声造影剂、光敏剂组成的组中的一种或多种；
    优选的，所述放射性核素选自由110In、111In、177Lu、18F、52Fe、62Cu、64Cu、67Cu、67Ga、68Ga、86Y、90Y、89Zr、94mTc、94Tc、99mTc、120I、123I、124I、125I、131I、154-158Gd、32P、11C、13N、15O、186Re、188Re、51Mn、52mMn、55Co、72As、75Br、76Br、82mRb和83Sr组成的组中的一种或多种；
    优选的，所述顺磁离子选自由铬(III)、锰(II)、铁(III)、铁(II)、钴(II)、镍(II)、铜(II)、钕(III)、钐(III)、镱(III)、钆(III)、钒(II)、铽(III)、镝(III)、钬(III)和铒(III)组成的组中的一种或多种；
    优选的，所述荧光标记选自由Alexa 350、Alexa 405、Alexa 430、Alexa 488、Alexa 555、Alexa 647、AMCA、氨基吖啶、BODIPY 630/650、BODIPY 650/665、BODIPY-FL、BODIPY-R6G、BODIPY-TMR、BODIPY-TRX、5-羧基-4′，5′-二氯-2′，7′-二甲氧基荧光素、5-羧基-2′，4′，5′，7′-四氯荧光素、5-羧基荧光素、5-羧基罗丹明、6-羧基罗丹明、6-羧基 四甲基罗丹明、Cascade Blue、Cy2、Cy3、Cy5、Cy7、6-FAM、丹磺酰氯、荧光素、HEX、6-JOE、NBD(7-硝基苯并-2-氧杂-1，3-二唑)、Oregon Green 488、Oregon Green 500、Oregon Green514、Pacific Blue、邻苯二甲酸、对苯二甲酸、间苯二甲酸、甲酚固紫、甲酚蓝紫、亮甲酚蓝、对氨基苯甲酸、赤藓红、酞菁、偶氮甲碱、花青、黄嘌呤、琥珀酰荧光素、稀土金属穴状化合物、三双吡啶基二胺铕、铕穴状化合物或螯合物、二胺、双花青苷、La Jolla蓝染料、别藻蓝蛋白、allococyanin B、藻蓝蛋白C、藻蓝蛋白R、硫胺、藻红青蛋白、藻红蛋白R、REG、罗丹明绿、罗丹明异硫氰酸酯、罗丹明红、ROX、TAMRA、TET、TRIT(四甲基罗丹明异硫醇)、四甲基罗丹明和德克萨斯红组成的组中的一种或多种。
  10. 根据权利要求8或9所述的组合物，其特征在于，所述治疗剂选自由裸抗体、细胞毒素剂、药物、放射性核素、硼原子、免疫调节剂、抗凋亡试剂、光敏性治疗剂、免疫偶联物和寡核苷酸组成的组中的一种或多种；
    优选的，所述药物选自由地塞米松、双氯芬酸、萘丁美酮、美洛昔康、塞来昔布、甲氨蝶呤、环磷酰胺、硫唑嘌呤、环孢素A和长春新碱组成的组中的一种或多种；
    优选的，所述寡核苷酸选自由shRNA、miRNA和siRNA组成的组中的一种或多种；
    优选的，所述免疫调节剂选自由细胞因子、趋化因子、干细胞生长因子、淋巴毒素、造血因子、集落刺激因子(CSF)、干扰素、促红细胞生成素、促血小板生成素、白介素(IL)、粒细胞-集落刺激因子(G-CSF)、粒细胞巨噬细胞-集落刺激因子(GM-CSF)和干细胞生长因子组成的组中的一种或多种；
    优选的，所述放射性核素选自由111In、111At、177Lu、211Bi、212Bi、213Bi、211At、62Cu、67Cu、90Y、125I、131I、133I、32P、33P、47Sc、111Ag、67Ga、153Sm、161Tb、152Dy、166Dy、161Ho、166Ho、186Re、188Re、189Re、211Pb、212Pb、223Ra、225Ac、77As、89Sr、99Mo、105Rh、149Pm、169Er、194Ir、58Co、80mBr、99mTc、103mRh、109Pt、119Sb、189mOs、192Ir、219Rn、215Po、221Fr、255Fm、11C、13N、15O、75Br、198Au、199Au、224Ac、77Br、113mIn、95Ru、97Ru、103Ru、105Ru、107Hg、203Hg、121mTe、122mTe、125mTe、165Tm、167Tm、168Tm、197Pt、109Pd、142Pr、143Pr、161Tb、57Co、58Co、51Cr、59Fe、75Se、201Tl、76Br和169Yb组成的组中的一种或多种。
  11. 权利要求7～10任一项所述的组合物在制备用于预防和/或治疗与IL-17A过量表达和/或释放相关的疾病的药物中的应用；
    优选的，所述疾病选自由气道炎症、哮喘、支气管哮喘、过敏性哮喘、慢性阻塞性肺病、特发性肺纤维化、类风湿性关节炎、骨关节炎、强直性脊柱炎、银屑病关节炎、银屑病、多发性硬化症、系统性硬化症、系统性红斑狼疮、狼疮肾炎、硬皮病、溃疡性结肠炎、炎性肠病、葡萄膜炎、幽门螺杆菌相关性胃炎、骨质疏松、骨质侵蚀、腹膜内脓肿和粘连、艾迪生氏病、丙种球蛋白缺乏症、斑秃、乳糜泻、查加斯病，克隆氏病、同种异体移植排斥、白塞氏病、败血症、脓毒性或内毒素性休克以及缺血组成的组中的任意一种。
  12. 权利要求1-5任一项所述的能够特异性地结合IL-17A的抗体及其功能片段在制备用于预防和/或治疗与IL-17A过量表达和/或释放相关的疾病的药物中的应用；优选的，所述疾病选自由气道炎症、哮喘、支气管哮喘、过敏性哮喘、慢性阻塞性肺病、特发性肺纤维化、类风湿性关节炎、骨关节炎、强直性脊柱炎、银屑病关节炎、银屑病、多发性硬化症、系统性硬化症、系统性红斑狼疮、狼疮肾炎、硬皮病、溃疡性结肠炎、炎性肠病、葡萄膜炎、幽门螺杆菌相关性胃炎、骨质疏松、骨质侵蚀、腹膜内脓肿和粘连、艾迪生氏病、丙种球蛋白缺乏症、斑秃、乳糜泻、查加斯病，克隆氏病、同种异体移植排斥、白塞氏病、败血症、脓毒性或内毒素性休克以及缺血组成的组中的任意一种。
  13. 一种备用于预防和/或治疗与IL-17A过量表达和/或释放相关的疾病的药物，其特征在于，所述药物含有权利要求1-5任一项所述的能够特异性地结合IL-17A的抗体及其功能片段以及医药学上可接受的载体；
    或者，所述药物含有权利要求10-13任一项所述的组合物以及医药学上可接受的载体；优选的，所述疾病选自由气道炎症、哮喘、支气管哮喘、过敏性哮喘、慢性阻塞性肺病、 特发性肺纤维化、类风湿性关节炎、骨关节炎、强直性脊柱炎、银屑病关节炎、银屑病、多发性硬化症、系统性硬化症、系统性红斑狼疮、狼疮肾炎、硬皮病、溃疡性结肠炎、炎性肠病、葡萄膜炎、幽门螺杆菌相关性胃炎、骨质疏松、骨质侵蚀、腹膜内脓肿和粘连、艾迪生氏病、丙种球蛋白缺乏症、斑秃、乳糜泻、查加斯病，克隆氏病、同种异体移植排斥、白塞氏病、败血症、脓毒性或内毒素性休克以及缺血组成的组中的任意一种。
  14. 一种预防和/或治疗与IL-17A过量表达和/或释放相关的疾病的方法，其特征在于，向个体施用如权利要求13所述的药物。
PCT/CN2017/101083 2016-09-14 2017-09-08 一种能够特异性地结合il-17a的抗体及其功能片段 Ceased WO2018050028A1 (zh)

Priority Applications (19)

Application Number Priority Date Filing Date Title
KR1020197010362A KR102329490B1 (ko) 2016-09-14 2017-09-08 Ｉｌ-１７ａ에 특이적으로 결합하는 항체 및 그의 기능성 단편
US16/332,900 US11072651B2 (en) 2016-09-14 2017-09-08 Antibody specifically binding to IL-17A, encoding nucleic acid, and method of using the antibody
CN201780056725.4A CN109715660A (zh) 2016-09-14 2017-09-08 一种能够特异性地结合il-17a的抗体及其功能片段
IL265350A IL265350B2 (en) 2016-09-14 2017-09-08 Antibody specifically binding to il-17a and functional fragment thereof
MX2019002970A MX2019002970A (es) 2016-09-14 2017-09-08 Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo.
ES17850230T ES2905917T3 (es) 2016-09-14 2017-09-08 Anticuerpo que se une específicamente a IL-17A y fragmento funcional del mismo
PE2019000527A PE20191075A1 (es) 2016-09-14 2017-09-08 Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo
BR112019004990A BR112019004990A2 (pt) 2016-09-14 2017-09-08 anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
EA201990673A EA201990673A1 (ru) 2016-09-14 2017-09-08 Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
JP2019535432A JP6802381B2 (ja) 2016-09-14 2017-09-08 Ｉｌ−１７ａに特異的に結合する可能な抗体及びその機能的断片
EP17850230.8A EP3514176B1 (en) 2016-09-14 2017-09-08 Antibody specifically binding to il-17a and functional fragment thereof
TNP/2019/000082A TN2019000082A1 (en) 2016-09-14 2017-09-08 Antibody specifically binding to il-17a and functional fragment thereof
MYPI2019001350A MY185578A (en) 2016-09-14 2017-09-08 Antibody specifically binding to il-17a and functional fragment thereof
CA3036913A CA3036913C (en) 2016-09-14 2017-09-08 Antibody specifically binding to il-17a and functional fragment thereof
NZ752189A NZ752189B2 (en) 2016-09-14 2017-09-08 Antibody specifically binding to il-17a and functional fragment thereof
AU2017328310A AU2017328310B2 (en) 2016-09-14 2017-09-08 Antibody specifically binding to IL-17A and functional fragment thereof
SA519401307A SA519401307B1 (ar) 2016-09-14 2019-03-13 جسم مضاد يرتبط بصورة خاصة بـإنترلوكين 17أ وشظية وظيفية منه
CONC2019/0002370A CO2019002370A2 (es) 2016-09-14 2019-03-14 Anticuerpo que se une específicamente a il-17a y fragmento funcional del mismo
PH12019500551A PH12019500551A1 (en) 2016-09-14 2019-03-14 Antibody specifically binding to il-17a and functional fragment thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610827097.2 2016-09-14
CN201610827097 2016-09-14

Publications (1)

Publication Number Publication Date
WO2018050028A1 true WO2018050028A1 (zh) 2018-03-22

Family

ID=60980760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/101083 Ceased WO2018050028A1 (zh) 2016-09-14 2017-09-08 一种能够特异性地结合il-17a的抗体及其功能片段

Country Status (22)

Country Link
US (1) US11072651B2 (zh)
EP (1) EP3514176B1 (zh)
JP (1) JP6802381B2 (zh)
KR (1) KR102329490B1 (zh)
CN (2) CN109715660A (zh)
AU (1) AU2017328310B2 (zh)
BR (1) BR112019004990A2 (zh)
CA (1) CA3036913C (zh)
CL (1) CL2019000659A1 (zh)
CO (1) CO2019002370A2 (zh)
DO (1) DOP2019000062A (zh)
EA (1) EA201990673A1 (zh)
EC (1) ECSP19018356A (zh)
ES (1) ES2905917T3 (zh)
IL (1) IL265350B2 (zh)
MX (1) MX2019002970A (zh)
MY (1) MY185578A (zh)
PE (1) PE20191075A1 (zh)
PH (1) PH12019500551A1 (zh)
SA (1) SA519401307B1 (zh)
TN (1) TN2019000082A1 (zh)
WO (1) WO2018050028A1 (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109402178A (zh) * 2018-11-16 2019-03-01 佛山科学技术学院 一种小鼠精原干细胞高效重编程的方法及应用
CN110124030A (zh) * 2019-06-10 2019-08-16 通化东宝生物科技有限公司 一种苏金单抗注射液及其制备方法
WO2020093990A1 (zh) 2018-11-05 2020-05-14 北京韩美药品有限公司 抗TNFα/抗IL‐17A天然抗体结构样异源二聚体形式双特异抗体及其制备
JP2022513224A (ja) * 2018-12-12 2022-02-07 上海君▲実▼生物医▲薬▼科技股▲分▼有限公司 抗ｉｌ‐１７ａ抗体及びその適用
RU2816204C2 (ru) * 2018-12-12 2024-03-27 Шанхай Цзюньши Биосайенсиз Ко., Лтд. Антитело против il-17a и его применение

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2019000082A1 (en) * 2016-09-14 2020-07-15 Beijing hanmi pharm co ltd Antibody specifically binding to il-17a and functional fragment thereof
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
CN110551215A (zh) * 2018-05-30 2019-12-10 中山康方生物医药有限公司 抗白细胞介素-17a抗体、其药物组合物及其用途
TWI874341B (zh) * 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
CN114127108A (zh) * 2019-07-30 2022-03-01 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
CN116024212A (zh) * 2022-07-29 2023-04-28 硅羿科技（上海）有限公司 抑制IL-25基因表达的siRNA及其应用
CN117820478B (zh) * 2023-12-29 2024-10-29 北京贝来药业有限公司 纳米抗体的串联分子及其在疾病治疗中的用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646690A (zh) * 2006-08-11 2010-02-10 先灵公司 抗il-17a抗体
CN104231080A (zh) * 2013-03-15 2014-12-24 中国医学科学院药物研究所 全人源抗人白介素17a单链抗体
WO2015070697A1 (zh) * 2013-11-18 2015-05-21 上海恒瑞医药有限公司 Il-17a结合物及其用途
CN104684571A (zh) * 2012-09-21 2015-06-03 科瓦根股份公司 新的il-17a结合分子及其医学应用
WO2015137843A1 (ru) * 2014-03-14 2015-09-17 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
CN105073775A (zh) * 2013-02-08 2015-11-18 诺华股份有限公司 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途
WO2016113557A1 (en) * 2015-01-12 2016-07-21 Crescendo Biologics Limited Il-17a binding proteins

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10140492A1 (de) 2001-08-17 2003-08-14 Gruenenthal Gmbh Hydrate von gegebenenfalls substituierten 2-(2-Pyridinyl)methylthio-1H-benzimidazolen und Verfahren zu ihrer Herstellung
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
DK1963368T6 (da) 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
EP1996622A2 (en) 2006-03-10 2008-12-03 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
NZ588674A (en) 2008-05-05 2013-02-22 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
ES2493042T3 (es) 2008-09-29 2014-09-11 Roche Glycart Ag Anticuerpos contra la IL-17 humana y usos de los mismos
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
AU2010313304B2 (en) * 2009-10-30 2015-08-20 Janssen Biotech, Inc. IL-17A antagonists
AU2012206431B2 (en) 2011-01-14 2015-04-30 UCB Biopharma SRL Antibody molecules which bind IL-17A and IL-17F
JP6362587B2 (ja) 2012-05-22 2018-07-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｌ−１７ａ／ｆｉｌ−２３二重特異性抗体およびその使用
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CN108251431B (zh) * 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
TN2019000082A1 (en) * 2016-09-14 2020-07-15 Beijing hanmi pharm co ltd Antibody specifically binding to il-17a and functional fragment thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646690A (zh) * 2006-08-11 2010-02-10 先灵公司 抗il-17a抗体
CN104684571A (zh) * 2012-09-21 2015-06-03 科瓦根股份公司 新的il-17a结合分子及其医学应用
CN105073775A (zh) * 2013-02-08 2015-11-18 诺华股份有限公司 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途
CN104231080A (zh) * 2013-03-15 2014-12-24 中国医学科学院药物研究所 全人源抗人白介素17a单链抗体
WO2015070697A1 (zh) * 2013-11-18 2015-05-21 上海恒瑞医药有限公司 Il-17a结合物及其用途
WO2015137843A1 (ru) * 2014-03-14 2015-09-17 Закрытое Акционерное Общество "Биокад" Анти-il-17-антитела, способ их получения и способ применения
WO2016113557A1 (en) * 2015-01-12 2016-07-21 Crescendo Biologics Limited Il-17a binding proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3514176A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020093990A1 (zh) 2018-11-05 2020-05-14 北京韩美药品有限公司 抗TNFα/抗IL‐17A天然抗体结构样异源二聚体形式双特异抗体及其制备
US20220010006A1 (en) * 2018-11-05 2022-01-13 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-tnfalpha/anti il - 17a natural antibody structure-like heterodimer form of bispecific antibody and preparation method therefor
US12325743B2 (en) * 2018-11-05 2025-06-10 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-TNFα/anti IL-17A natural antibody structure-like heterodimer form of bispecific antibody and preparation method therefor
CN109402178A (zh) * 2018-11-16 2019-03-01 佛山科学技术学院 一种小鼠精原干细胞高效重编程的方法及应用
CN109402178B (zh) * 2018-11-16 2021-08-03 佛山科学技术学院 一种小鼠精原干细胞高效重编程的方法及应用
JP2022513224A (ja) * 2018-12-12 2022-02-07 上海君▲実▼生物医▲薬▼科技股▲分▼有限公司 抗ｉｌ‐１７ａ抗体及びその適用
RU2816204C2 (ru) * 2018-12-12 2024-03-27 Шанхай Цзюньши Биосайенсиз Ко., Лтд. Антитело против il-17a и его применение
US12209124B2 (en) 2018-12-12 2025-01-28 Shanghai Junshi Biosciences Co., Ltd. Anti-IL-17A antibody and use thereof
JP7696291B2 (ja) 2018-12-12 2025-06-20 上海君▲実▼生物医▲薬▼科技股▲分▼有限公司 抗ｉｌ‐１７ａ抗体及びその適用
CN110124030A (zh) * 2019-06-10 2019-08-16 通化东宝生物科技有限公司 一种苏金单抗注射液及其制备方法

Also Published As

Publication number Publication date
SA519401307B1 (ar) 2023-11-08
PH12019500551A1 (en) 2019-11-04
EP3514176A4 (en) 2020-04-29
CA3036913C (en) 2023-05-16
IL265350B2 (en) 2024-10-01
ES2905917T3 (es) 2022-04-12
BR112019004990A2 (pt) 2019-06-04
CL2019000659A1 (es) 2019-07-19
ECSP19018356A (es) 2019-05-31
US11072651B2 (en) 2021-07-27
JP6802381B2 (ja) 2020-12-16
CN107556382A (zh) 2018-01-09
CA3036913A1 (en) 2018-03-22
MX2019002970A (es) 2019-09-18
IL265350A (en) 2019-05-30
CN109715660A (zh) 2019-05-03
EA201990673A1 (ru) 2019-08-30
JP2020500206A (ja) 2020-01-09
CO2019002370A2 (es) 2019-05-10
TN2019000082A1 (en) 2020-07-15
AU2017328310A1 (en) 2019-04-18
KR20190045348A (ko) 2019-05-02
CN107556382B (zh) 2021-04-20
KR102329490B1 (ko) 2021-11-23
US20190256588A1 (en) 2019-08-22
DOP2019000062A (es) 2019-05-31
AU2017328310B2 (en) 2020-10-15
MY185578A (en) 2021-05-22
NZ752189A (en) 2021-10-29
EP3514176B1 (en) 2021-12-15
EP3514176A1 (en) 2019-07-24
PE20191075A1 (es) 2019-08-20
IL265350B1 (en) 2024-06-01
AU2017328310A9 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
WO2018050028A1 (zh) 一种能够特异性地结合il-17a的抗体及其功能片段
US9592293B2 (en) Interleukin-13 binding proteins
WO2018050027A1 (zh) 一种能够特异性地结合pd-1的抗体及其功能片段
EP4047022A1 (en) Anti-cd40 antibodies and uses thereof
CN111051343B (zh) Il-6r抗体、其抗原结合片段及医药用途
US20200277366A1 (en) MULTI-SPECIFIC ANTIBODY MOLECULES HAVING SPECIFICITY FOR TNF-ALPHA, IL-17A and IL-17F
WO2021023274A1 (zh) 人源化抗TNFα抗体及其用途
CN102675460B (zh) 抗肿瘤坏死因子α的人源化抗体
TW201333034A (zh) 新穎抗人類ｃｔｇｆ抗體
NZ752189B2 (en) Antibody specifically binding to il-17a and functional fragment thereof
EA042457B1 (ru) Антитело, специфически связывающееся с il-17a, композиция и конъюгат на его основе и применение в лечении заболевания, связанного со сверхэкспрессией и/или избыточным высвобождением il-17a
HK40005565A (zh) 一种能够特异性地结合il-17a的抗体及其功能片段
CN120887988A (zh) 犬白细胞介素-31抗体及其应用
EA041843B1 (ru) Антитело, специфически связывающееся с pd-1, и его применения

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17850230

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019535432

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3036913

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: NC2019/0002370

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019004990

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: DZP2019000169

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 20197010362

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017328310

Country of ref document: AU

Date of ref document: 20170908

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017850230

Country of ref document: EP

Effective date: 20190415

WWP Wipo information: published in national office

Ref document number: NC2019/0002370

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112019004990

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190314

WWG Wipo information: grant in national office

Ref document number: NC2019/0002370

Country of ref document: CO